INSTITUTO DE CIENCIAS BIOMÉDICAS ABEL SALAZAR
INSTITUTO DE CIENCIAS DA VIDA E CIENCIAS DA VIDA E SAUDE (ICVS)
NELMA ISABEL AROUCA PÉRTEGA GOMES
ROLE OF MONOCARBOXYLATE TRANSPORTERS IN PROSTATE CARCINOMA
Tese de Candida u a ao g au de Dou o em
Ciências (Especialidade em: Pa ologia e
Gené ica Molecula ), subme ida ao Ins i u o de
Ciências Biomédicas Abel Salaza da
Uni e sidade do Po o.
O ien ado – Ma ia de Fá ima Monginho
Bal aza
Ca ego ia – P o esso a Auxilia
A iliação – Ins i u o de Ciências da Vida e
Saúde, B aga, Po ugal; Escola de Ciências da
Saúde, Uni e sidade do Minho, B aga, Po ugal.
Co-o ien ado – Ca los Albe o da Sil a Lopes
Ca ego ia – P o esso Ca ed á ico
A iliação – Ins i u o de Ciências Biomédicas
Abel Salaza da Uni e sidade do Po o, Po o,
Po ugal.
A ese de dou o amen o aqui ap esen ada
oi desen ol ida no âmbi o de inanciamen o
pela Fundação pa a a Ciência e Tecnologia
(FCT) a a és de uma bolsa indi idual de
dou o amen o, com a e e ência
SFRH/BD/61027/2009, e do p ojec o “Role o
Monoca boxyla e T anspo e s (MCTs) in he
me abolism o p os a e cance ”, com a
e e ência PTDC/SAL-MET/113415/2009, no
âmbi o do P og ama Ope acional Temá ico
Fac o es de Compe i i idade (COMPETE) do
Quad o Comuni á io de Apoio III e co- inanciado
pelo Fundo Comuni á io Eu opeu FEDER.
ACKNOWLEDGEMENTS
I would like o hank my supe iso P o . Fá ima Bal aza , o gi ing me he
oppo uni y o en e in his “Scien i ic Wo ld”. Thank you o in oducing me o
Cance and Me abolism esea ch ield and o always gi ing me he
oppo uni y/libe y o es ablish collabo a ions wi h o he esea ch g oups du ing my
PhD. This was ex emely aluable du ing my PhD jou ney.
To P o esso Ca los Lopes as co-supe iso o his wo k and Di ec o o he
Pa hology and Molecula Gene ics PhD P og amme o allowing me o join his
Cou se, u ning his jou ney in o a eal lea ning expe ience.
A e y special hanks o D . José Ramon Vizcaino o accep ing me a he
Pa hology Depa men o Cen o Hospi ala do Po o and o accep o be pa o
ou P ojec . Thank you o you scien i ic supe ision, op imism, pa ience, ideas
and iendship. My hesis would no be he same wi hou ou equen
scien i ic/specula i e alks. Thank you so much!!!
A special hank o P o esso Da id Neal and Lee F ye a Cance Resea ch UK
Camb idge Ins i u e/Uni e si y o Camb idge o allowing me o join hei lab and
de elop my skills and scien i ic knowledge in such a high-quali y esea ch Ins i u e.
A a p o essional and pe sonal le el his was a huge expe ience o me. Thanks
o s ill belie ing my wo k. I can jus p omise ha I will always do my bes o
co espond you expec a ions. Thank you!!
Many hanks o all ha in one way o ano he ha e collabo a ed wi h me, ecei ing
me in mos cases a hei labs. P o esso Rui Hen ique, P o esso Ca men
Je ónimo and P o esso Alexand e Lobo da Cunha. I also would like o hank Elsa
Oli ei a and Ca los Gou eia, hank you all. A special hanks o D a. Daniela
Ribei o and D . Valdema Máximo, many hanks o belie e in my ideas and o
helping me o each my aims!!
I also wan o hank all my iends inside and ou side he lab:

A ICVS I would like o hank Ca ina and Rica do. Thanks o all he good
momen s inside and ou side he lab, I am su e ha we will be iends o e e no
ma e wha . Filipe Pin o and Isabel Valença my dea pa ne s in pa y and wo k.
I is indeed possible o es ablish good collabo a i e wo k and ha e un a he same
ime. I hink i is one o he bes combina ions e e . Thanks o ha !!
To “HOXAs” g oup, hank you gi ls o all he unny momen s, lunch imes, dinne s,
co ees and so on. Wish you all he bes .
My iends and collgues a CRI: Vinny, Mohammad, Cha lie, Sa ah, Jan, Ka an,
Helen, S e e, Ha ee , An onio o all hei iendship and suppo and o allowing
me o lea n new hings om you expe ience and o sha ing wi h me expe ise
inside and ou side he lab. A e y special hanks o Sa ah Ju meis e who was
my e e y hou suppo in many di e en ways. Thank you o always be a ailable
o each me some hing new and o you suppo and encou agemen o be and o
do be e . Thank you o all you s a is ical suppo and e eshing ideas abou how
o look a my esul s.
To all my iends ou o he lab, especially Sil ia, Bia, Liliana, Vânia e Do a, Aldina
and Diana o all he good imes, o hei suppo , iendship and o accep ing me
as I am u ning e e y momen ha I was down in o a good momen . Fo always
encou aging me o he bes , hank you my iends.
To Julia and Jjonas o being he bes housema es e e !!!
Finally I would like o show all my g a i ude o my amily, namely my pa en s and
b o he , who always suppo ed me. Thank you o helping me o deal wi h my
us a ions and ba ie s along his jou ney. Thank you o aising me and o all he
encou agemen o be a be e pe son gi ing me he eedom o do my choices and
lea n om hem.
I would like o dedica e his hesis o all o you!!
We canno do science alone!!!
DIRETIVAS LEGAIS
No cump imen o do dispos o no Dec e o de Lei n º 230/2009, decla a-se que a
au o a des a disse ação pa icipou a i amen e na execução do abalho
expe imen al que es e e na o igem dos esul ados ap esen ados bem como na
edação dos espe i os manusc i os.
Fazem pa e des a ese os seguin es a igos publicados ou em p epa ação:
Pé ega-Gomes N, Vizcaíno JR, Mi anda-Gonçal es V, Pinhei o C, Sil a J,
Pe ei a H, Mon ei o P, Hen ique RM, Reis RM, Lopes C, Bal aza F.
“Monoca boxyla e anspo e 4 (MCT4) and CD147 o e exp ession is
associa ed wi h poo p ognosis in p os a e cance .” BMC Cance . 2011 Jul
25;11:312. doi: 10.1186/1471-2407-11-312. (Ci ações ISI: 19)
Pé ega-Gomes N, Vizcaíno JR, Gou eia C, Je ónimo C, Hen ique RM, Lopes C,
Bal aza F. “Monoca boxyla e anspo e 2 (MCT2) as pu a i e bioma ke in
p os a e cance .” P os a e. 2013 May;73(7):763-9. doi: 10.1002/p os.22620.
Epub 2012 No 28.
Pé ega-Gomes N, Valença I, Vizcaíno JR, Ribei o D, Bal aza F. “Localiza ion
o MCT2 a pe oxisomes is associa ed wi h malignan ans o ma ion in
p os a e cance ” o be published in an in e na ional scien i ic pe iodical wi h
e e ees.
Pé ega-Gomes N, Vizcaíno JR, Sousa S, Coelho R, A ig J, Ju meis e S,
Oli ei a E, Pe ei a L, Pinhei o C, Je ónimo C, Hen ique RM, Lobo da Cunha A,
Lopes C, Maximo V and Bal aza F. “Me abolic he e ogenei y in p os a e cance
is linked o disease p og ession and agg essi eness” o be published in an
in e na ional scien i ic pe iodical wi h e e ees.
Pé ega-Gomes N, Vizcaíno JR,Gou eia C, Lopes C and Bal aza F. “A lac a e
shu le sys em be ween umou and s omal cells is associa ed wi h poo
p ognosis in p os a e cance ” o be published in an in e na ional scien i ic
pe iodical wi h e e ees.
Pé ega-Gomes N and Bal aza F. “Explo a ion o MCTs as po en ial
he apeu ic a ge s in p os a e cance ” in i ed wo k o be published in
Ad ances in P os a e Cance Resea ch and T ea men jou nal.
TABLE OF CONTENTS
Abb e ia ion Lis …………………………………………………………….…i
Abs ac …………………………………………………………………………iii
Resumo………………………………………………………………………....
Aims and Thesis Layou ……………………………………………………... ii
Chap e 1. Gene al In oduc ion………………………………………......3
1.1 Rep og amming ene gy me abolism as an eme ging hallma k o
cance ………………………………………………………………………3
1.1.1 The Wa bu g e ec as he basis o explo ed al e ed cellula
Me abolism in cance …………………………………………………………4
1.1.2 A Me abolic swi ch ha con e s ad an age o cance cells…...6
1.1.2.1 Why cance cells p e e ae obic glycoysis…………………...6
1.1.2.2 A deepe insigh in o hypoxia and Lac a e expo : G ea
con ibu o s o malignancy………………………………………9
1.2 Monoca boxyla e T anspo e s (MCTs) in he con ex o cellula
me abolism…………………………………………………………….......13
1.2.1 The MCT amily…………………………………………………….....14
1.2.1.1 MCT1……………………………………………………………......16
1.2.1.2 MCT2……………………………………………………………......17
1.2.1.3 MCT4………………………………………………………….…….18
1.2.1.4 O he MCT iso o ms…………………………………………..….18
1.2.2 MCTs egula ion………………………………………………………20
1.2.2.1 T ansc ip ional Le el……………………………………………..20
1.2.2.2 Pos -T ansc ip ional Le el………………………………………22
1.2.2.3 T anspo e Ac i i y Le el………………………….…………....23
1.2.2.4 Ho monal Regula ion………………………………………….....25
1.2.3 MCTs inhibi ion………………………………………………….……25
1.2.3.1 The Classical MCT Inhibi o : CHC………………………..........26
1.2.3.2 Speci ic MCT Inhibi o s…………………………………………..27
1.2.3.3 O he MCT inhibi o s……………………………………………..27
i
ep esen p omising he apeu ic a ge s in di e en phases o neoplas ic
ans o ma ion and p og ession.

RESUMO
O concei o de al e ações me abólicas so idas pelas células umo ais oi
ecen emen e incluído nas p incipais al e ações so idas no co ex o de
ans o mação maligna. Uma das p incipais ca ac e ís icas me abólicas das
células umo ais consis e no seu ele ado consumo de glucose e consequen e
p odução de lac a o.
De modo a assegu a o ápido e luxo de lac a o, a maio ia das células
malignas exp essam ele ados ní eis de anspo ado es de monoca boxila os
(MCTs). A inibição des es anspo ado es em sido ap esen ada como um bom
al o pa a quimio e apia e á ios es udos in i o demons a am já o po encial
des a abo dagem, no en an o, no con ex o do ca cinoma da p ós a a o impac o da
inibição MCTs assim como a sua egulação du an e a p og essão umo al
con inua em g ande pa e desconhecida. Adicionalmen e, ainda não es á cla o
qual é a ia me abólica p edominan e no canc o da p ós a a e, po an o, qual a
que se ap esen a como al o mais ap op iado pa a a e apia.
O p incipal obje i o des e abalho oi in es iga a exp essão e egulação dos
MCTs du an e a p og essão do ca cinoma da p ós a a e se es es anspo ado es
pode iam ep esen a al os p omisso es no a amen o des a doença.
A exp essão de MCTs jun amen e com ou as p o eínas elacionadas com o
me abolismo oi es udada usando uma g ande sé ie de ecidos de p ós a a
humana e o seu alo clínico-pa ológico oi a aliado. Es udos in i o o am
ealizados a im de comp eende como a iam as exigências me abólicas das
células du an e a p og essão umo al e de que o ma es as mudanças pode iam
ep esen a al os e apêu icos pa a a doença, dando especial ên ase aos MCTs
nes e con ex o.
Os esul ados ob idos indicam que o ca cinoma da p ós a a não é ão glicolí ico
como ou os ipos de umo e que o aumen o da glicólise é p incipalmen e
encon ado num es adio mais a ançado da doença. Foi obse ado que di e en es
iso o mas de MCTs es ão di e encialmen e exp essas em di e sas ases de
p og essão do ca cinoma da p ós a a e po encialmen e elacionados com
di e en es ias me abólicas e po an o não es i as ao seu clássico papel de
anspo ado es de lac a o na memb ana ci oplasmá ica e que a inibição das
di e en es iso o mas em di e en es condições a e a a iabilidade e p oli e ação
i
das células malignas. Em conclusão, os esul ados ap esen ados nes a ese são
pionei os na comp eensão das exigências me abólicas do ca cinoma da p ós a a
du an e a p og essão umo al, con ex ualizando os MCTs como possí eis al os
e apêu icos em di e en es ases da ans o mação neoplásica e p og essão
maligna.
ii
AIMS AND THESIS LAYOUT
Me abolic changes du ing malignan ans o ma ion ha e been no ed o many
yea s. O o Wa bu g i s epo ed ha cance cells p e e en ially ely on glycolysis
o ene gy p oduc ion, e en in he p esence o oxygen, leading o p oduc ion o
high le els o lac a e. The c ucial ole o lac a e e lux and exchange wi hin he
umou mic oen i onmen d ew a en ion o monoca boxyla e anspo e s (MCTs).
MCTs ha e been poin ed as p omising a ge s in cance he apy and desc ibed in
a la ge a ie y o umou s, howe e , s udies showing how hese iso o ms
con ibu e o he acquisi ion o he malignan pheno ype a e sca ce and ega ding
p os a e cance i is o ally unknown.
The main aim o his hesis was o cha ac e ize MCTs exp ession in p os a e
issues, namely p os a e cance , as well as o gi e a con ibu ion o unde s and he
ole o MCTs in p os a e cance main enance and p og ession p o iding e idence
o he exploi a ion o MCTs as po en ial a ge s o p os a e cance he apy.
This hesis is o ganized in 7 ela ed chap e s, aiming o show he mos impo an
esul s ob ained du ing he de elopmen o his scien i ic p ojec .
In Chap e 1 a gene al in oduc ion o he Hallma ks o cance wi h a special
emphasis o al e ed cellula me abolism as a new hallma k o cance and he
“Wa bu g e ec ” as he basis o explo e MCTs as sui able a ge s o cance
he apy is p o ided. Also, he cu en knowledge on p os a e cance me abolism is
e iewed in his chap e .
In Chap e s 2-6 majo indings abou me abolic changes ac oss p os a e cance
malignan ans o ma ion as well as he alue o using MCTs as a ge s o
p os a e cance he apy is p esen ed. These chap e s include esul s al eady
published o submi ed o publica ion in in e na ional scien i ic pe iodicals wi h
e e ees, gi ing a con ibu ion o unde s and he ole o MCTs in he con ex o
p os a e cance . In Chap e 2 he exp ession o MCTs in p os a e issues and he
clinico-pa hological alue o his exp ession is p esen ed. Chap e 3 explo es
mo e deeply he ole o MCT2 in p os a e cance me abolism. In Chap e 4 a
panel o key me abolic- ela ed p o eins exp ession was s udied in an e en bigge
casuis ic o p os a e issues. In i o assays we e also pe o med showing
ii
impo an me abolic al e a ions ac oss p os a e cance malignan ans o ma ion
and how MCTs inhibi ion a ec s p os a e cance cells in di e en umou
en i onmen condi ion. In Chap e 5 an e o o unde s and he me abolic
al e a ions in he s oma ha su ounds p os a e umou s is p esen ed. Finally,
Chap e 6 p esen s an insigh on MCTs egula ion ac oss p os a e cance
p og ession and in Chap e 7, he main conclusions o Chap e s 2-6 a e
summa ized and some impo an u u e di ec ions a e sugges ed. Each o hese
chap e s has hei own bibliog aphy sec ion.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
CHAPTER 1. GENERAL INTRODUCTION

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
3
CHAPTER 1. GENERAL INTRODUCTION
1.1 Rep og amming o ene gy me abolism as an eme ging Hallma k o
Cance
Ad ances in cance esea ch ha e gene a ed a ich bu also ex emely
complex knowledge e ealing cance as a disease ha in ol es se e al dynamic
changes. In o de o o ganize he complexi y o cance , he biological capabili ies
acqui ed du ing he mul is ep de elopmen o human umou s and sha ed by all
cance s we e g ouped and denomina ed as he “hallma ks o cance ”. Sus aining
p oli e a i e signaling, e ading g ow h supp esso s, esis ing cell dea h, enabling
eplica i e immo ali y, inducing angiogenesis, and ac i a ing in asion and
me as asis we e he ai s es ablished in o de o c ea e an o ganized p inciple ha
p o ides a logical amewo k o unde s and he di e si y o neoplas ic disease [1].
La ely, new hallma ks ha e eme ged and ep og amming o ene gy me abolism
was conside ed an eme ging hallma k o cance since i was ecognized ha he
ch onic and uncon olled cell p oli e a ion ha ep esen s he essence o
neoplas ic disease in ol es also adjus men s o ene gy me abolism in o de o uel
cell g ow h and di ision [2]. Figu e 1 ep esen s he las e sion o he “Hallma ks
o cance ”.
Figu e 1. The Hallma ks o Cance [2].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
4
1.1.1 The Wa bu g e ec as he basis o explo e al e ed cellula me abolism
in cance
Al e ed ene gy me abolism is being p o ed o be as widesp ead in cance cells as
many o he o he cance -associa ed ai s ha ha e been accep ed as hallma ks
o cance . Howe e jus ecen ly a majo ele ance has been gi en o cance
me abolism, he obse a ion ha umou cells exhibi an al e ed me abolism
when compa ed o no mal cells was made almos one cen u y ago by he Nobel
P ize winne O o Wa bu g who desc ibed i as he i s umou speci ic-al e a ion
[3]. Wa bu g desc ibed ha in con as o non-malignan cells, many ypes o
cance cells p e e glycolysis as he ATP sou ce, e en in he p esence o
abundan oxygen. I unde ae obic condi ions, no mal cells p ocess glucose, fi s
o py u a e ia glycolysis in he cy osol and hen o ca bon dioxide in he
mi ochond ia, unde anae obic condi ions, glycolysis is a o ed and ew py u a e
is send o he oxygen-consuming mi ochond ia. Wa bu g fi s obse ed ha cance
cells can ep og am hei glucose me abolism, and hus hei ene gy p oduc ion,
by limi ing hei ene gy me abolism la gely o glycolysis, leading o a s a e ha has
been called ‘‘ae obic glycolysis’’ (Figu e 2).
Figu e 2. Schema ic ep esen a ion o he di e ences be ween OXPHOS, anae obic glycolysis and
“ae obic glycolysis” (Wa bu g e ec ) [4].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
5
Glycolysis, he i s majo pa hway o cellula me abolism, occu s in he cy oplasm
and is unc ional e en in he absence o oxygen. While glycolysis is able o
p oduce ATP a high a es, i is conside ed a low e iciency pa hway because i
p oduces only wo ATP molecules pe glucose. In o de o compensa e o he
lowe e ficiency o ATP p oduc ion ob ained by glycolysis ela i e o mi ochond ial
oxida i e phospho yla ion, cance cells ma kedly inc eased up ake and u iliza ion
o glucose in many human umo ypes being he a e o en y highe han in
no mal cells [5-7]. This has p o en use ul o de ec umou s and also moni o hei
ea men , as i is he basis o he clinical use o posi on emission omog aphy
(PET) ha uses a adiolabeled analog o glucose (18F-fluo odeoxyglucose, FDG)
as a epo e [8]. FDG is ecognized as a subs a e o glucose anspo sys ems;
hus, he a e o en y o his glucose de i a e in o cells is de e mined by he
ac i i y o glucose anspo sys ems. Inside he cells, he accumula ion o he
adioac i e glucose analogue se es as a ead-ou o he a e o glucose en y
in o cells. Since umou cells exhibi enhanced glucose up ake compa ed o
adjacen no mal cells, PET is able o de ec umou s and di e en ia e hem om
no mal issue [9, 10] (Figu e 3).
Figu e 3. PET imaging wi h FDG o a pa ien wi h lymphoma. The medias inal nodes (pu ple a ow)
and sup a incula nodes (g een a ows) show high up ake o FDG, showing ha umou s in hese
nodes ha e high le els o FDG up ake. The bladde (yellow a ow) also has high ac i i y, because
o exc e ion o he adionuclide [11].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
12
accumula ion o HIF1-alpha, which would lead in u n o a s imula ion o he
glycoly ic pa hway by egula ing glycoly ic enzymes, p o iding an impo an
posi i e eedback in he con ex o cance . Mo eo e , lac a e was demons a ed o
s imula e molecules in ol ed in he p ocess o cance in asion and me as asis.
CD44, VEGF and ans o ming g ow h ac o (TGFB2) a e some o hem [35-39].
Besides glycolysis, i is impo an o ecognize ha he e a e o he pa hways ha
can also con ibu e o lac a e p oduc ion in solid umou s such as glu aminolysis
and se inolysis (Figu e 7) [40,41].
Figu e 7. O e iew o he me abolic pa hways leading o lac a e p oduc ion in cells (con inuous
lines). The discon inuous a ows indica e lac a e up ake and low inside oxida i e cance cells.
Besides being mainly an end-p oduc , lac a e expo ed migh also be a subs a e
o neighbo cells, a phenomenon known as “cell-cell lac a e shu le”, in which he
pe iphe al and oxygena ed oxida i e cells consume he lac a e p oduced by he
cen al and hypoxic glycoly ic cells (Figu e 8).

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
13
Figu e 8. Scheme ep esen ing in a umou al hypoxia and me abolic symbiosis.
The c ucial ole o lac a e e lux and exchange wi hin he umou
mic oen i onmen , d ew a en ion o monoca boxyla e anspo e s (MCTs) which
anspo monoca boxyla es such as lac a e ac oss he memb anes, and he e o e
play a cen al ole in cellula me abolism and me abolic communica ion be ween
issues.
1.2 Monoca boxyla e T anspo e s (MCTs) in he con ex o cellula
me abolism.
The anspo o monoca boxyla es ac oss he plasma memb ane was o iginally
hough o be ia non-ionic di usion o he ee acid, howe e , he demons a ion
ha lac a e and py u a e anspo in o human e y h ocy es could be s ongly
inhibi ed a e ea men wi h chemicals, allowed he iden i ica ion o a speci ic
monoca boxyla e anspo mechanism. The monoca boxyla e anspo was hen
cha ac e ized ex ensi ely in di e en cell ypes and he obse ed cha ac e is ics
led o he a ionale o o he exis ence o a amily o monoca boxyla e
anspo e s [42-43].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
14
1.2.1 The MCT Family
MCTs a e encoded by he SLC16 gene amily, which is conse ed among species,
including a , mouse, chicken and o he s. The amily is p esen ly composed by 14
membe s, iden i ied h ough sc eening o genomic and exp essed sequence ag
da abases [43].
These p o eins ca alyse he anspo o lac a e wi h a p o on, wi h no ene gy inpu
in ol ed in his p ocess [42, 44].
I is p edic ed ha he opology o MCTs consis s o 12 ansmemb ane domains
(TMDs) wi h he N- and C- e mini loca ed in he cy oplasm, as illus a ed in Figu e
9 o MCT1. The TMDs a e highly conse ed among iso o ms wi h he g ea es
sequence a ia ions obse ed in he C- e minus and he la ge in acellula loop
be ween TMDs 6 and 7, which has a ange o 29-105 amino acid esidues [45] .
This obse ed a iabili y is common o anspo e s wi h 12 TMDs and i is hough
ha hese sequence a ia ions a e ela ed o subs a e speci ici y o egula ion o
anspo ac i i y [44, 45]. Theo e ical p edic ions and expe imen al e idence
indica e ha none o he MCT amily membe s is glycosyla ed [46-49]. To unc ion,
an MCT ansloca es a p o on and a monoca boxyla e h ough he plasma
memb ane by an o de ed mechanism in which H+ binding is ollowed by
monoca boxyla e binding o he p o ona ed anspo e [49, 50]. The e o e, MCT
ac i i y is dependen on bo h besides subs a e concen a ion and p o on g adien
be ween he ex acellula and in acellula milieus.
Figu e 9. P oposed opology o MCT1. The model shown is ha p edic ed om he p ima y
sequence using hyd opa hy plo s and subsequen ly con i med by p o eoly ic clea age and labelling
expe imen s as desc ibed by Juel & Hales ap [44].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
15
Lac a e is indeed he monoca boxyla e whose anspo ac oss he plasma
memb ane is quan i a i ely mo e impo an , howe e , MCTs a e also impo an o
he anspo o many o he me abolically impo an monoca boxyla es such as
py u a e, he b anched-chain oxoacids de i ed om leucine, aline and isoleucine,
and he ke one bodies ace oace a e, β-hyd oxybu y a e and ace a e [45].
Consequen ly, MCTs ha e a cen al ole in mammalian cell me abolism and a e
c i ical o he communica ion be ween cells as illus a ed in Figu e 10.
Figu e 10. Me abolic pa hways in ol ing monoca boxyla e anspo ac oss he mi ochond ial and
plasma memb anes [45].
Besides being a amily o 14 membe s, only he i s ou (MCT1-MCT4) ha e been
demons a ed expe imen ally o acili a e he p o on-linked anspo o
me abolically impo an monoca boxyla es [46-49]. Since MCT3 is a e y
specialized MCT, being limi ed o he e inal pigmen and cho oid plexus epi helia
[50,51] his in oduc ion will only ocus on MCT1, MCT2 and MCT4 iso o ms,
whose unc ion is esponsible o he name o his amily o anspo e s [52-56].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
16
Figu e 11 shows ha MCT1-MCT4 a e associa ed in he same clus e p esen ing
high homology. Impo an ly, his clus e is ye sub-di ided in wo b anches MCT1-2
and MCT3-4 which co ela es wi h he anspo ed subs a e as well as he
a ini ies by which hose anspo is pe o med.
Figu e 11. Human MCT amily membe s’ phylog am, based on amino acid sequence. Boxes
limi ed by do s ep esen he main clus e s [57].
1.2.1.1 MCT1
Human MCT1 gene, SLC16A1 is loca ed on ch omosome 1 (1p13.2-p12) and
comp ises 5 coding exons. MCT1 unc ional p o ein is composed by 500 amino
acids and has a molecula weigh o 53.958 Dal ons [58].
Among he MCT amily, MCT1 iso o m is he mos well s udied and unc ionally
cha ac e ized membe , since i is he only MCT exp essed in human e y h ocy es.
Al hough ubiqui ously exp essed, MCT1 is especially p ominen in hea and ed
muscle, whe e i is up- egula ed in esponse o inc eased wo k, sugges ing a
special ole in lac ic acid oxida ion [59,60]. The wide pa e n o exp ession
obse ed o MCT1 may be explained by i s subs a e a ini ies ha indica e ha
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
17
MCT1, may be in ol ed in bo h up ake and e lux o monoca boxyla es om cells.
MCT1 anspo s a a ie y o subs a es including sho chain (C2-C5) unb anched
alipha ic monoca boxyla es such as ace a e and p opiona e. Monoca boxyla es
wi h C2 o C3 subs i u ions (excluding amino- and amido-) a e also anspo ed o
e en p e e ed (e.g py u a e, L-lac a e, ace oace a e and β- hyd oxybu y a e) (35-
37c). The simples monoca boxyla e, o ma e, is a poo subs a e whe eas
bica bona e; dica boxyla es, ica boxyla es and sulphona es a e no anspo ed.
Also MCT1 is s e eoselec i e o lac a e bu no o β-hyd oxybu y a e.
MCT1 was also ound in mi ochond ia [61,62] and pe oxisomes [63], whe e i is
belie ed o pa icipa e in a lac a e oxida ion complex o main ain o ganelle edox
and p ope unc ioning.
1.2.1.2 MCT2
MCT2 is encoded by he SLC16A7 gene loca ed in ch omosome 12 (12q13) and
comp ises 5 coding exons [64]. Al hough only one ansc ip is iden i ied, he e is
e idence o al e na i ely spliced mRNA species in human and a [51, 63], bu no
e idence o splice a ian s o he p o ein. This iso o m sha es app oxima ely 50%
sequence iden i y wi h MCT1, con ains 478 amino acids and has a molecula
weigh o 52,186 Da. The ac ha , when bo h MCT1 and MCT2 a e exp essed in
he same issue, he exp ession pa e n is cell-speci ic, sugges ed a dis inc
unc ional ole be ween hese iso o ms [64-68]. Subsequen exp ession o MCT2
in Xenopus oocy es e ealed i s unique biochemical ea u e o acili a ing he
p o on-linked anspo o especially py u a e, wi h a conside able high a ini y,
suppo ing he p e ious e idence o an al e na i e biological ole [69]. As so,
MCT2 also ca alysis he p o on-linked anspo o a ange o monoca boxyla es,
bu wi h a conside ably highe a ini y han MCT1.
As a highe a ini y anspo e , MCT2 has also a mo e es ic ed exp ession, being
adap ed o pe o m he up ake o monoca boxyla es in o cells. As a esul , MCT2
is ound in issues ha use lac a e as a espi a o y uel, like b ain o ca diac and
skele al muscle, kidney and li e we e lac a e is he majo gluconeogenic subs a e

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
18
[66,67,69,70]. As MCT1, MCT2 is also ound in mi ochond ia [71,72] and
pe oxisomes [63].
1.2.1.3 MCT4
MCT4 is encoded by he human SLC16A3 gene, which is loca ed in ch omosome
17 (17q25.3), comp ises 5 exons and 3 ansc ip s, wi h di e en ini ia ion si es bu
no di e ence in p o ein p oduc has been iden i ied. The p o ein is cons i u ed by
465 amino acids, co esponding o a molecula weigh o 49,469 Da. MCT4
demons a es ema kable simila i ies wi h MCT1 and in con as o MCT2 has a
b oade dis ibu ion. The p incipal di e ence be ween MCT4 and MCT1 iso o ms
lies on hei speci ic localiza ion and subs a e a ini ies. MCT4 shows a much
lowe a ini y o subs a es han MCT1 and MCT2. Acco dingly, MCT4 is
p edominan ly exp essed in glycoly ic cells such as whi e muscle and whi e blood
cells, sugges ing ha i s physiological unc ion is lac a e e lux and in ac , he
kine ic p ope ies o MCT4 show ha his iso o m is adap ed o he expo o
lac a e. This led o he hypo hesis ha MCT4 migh be o pa icula impo ance in
cells ha ely on high a es o glycoly ic me abolism o mee hei ene gy demands,
p oducing high amoun s o lac a e ha need o be apidly expo ed, such as
cance cells [73].
1.2.1.4 O he MCT iso o ms
O he MCT iso o ms a e being cha ac e ized in he las yea s. SLC18A2 (MCT8)
gene has been desc ibed as a hy oid ho mone anspo e [74] and mu a ions in
his gene ha e been associa ed wi h X linked se e e men al e a da ion and
neu ological dys unc ion [76-80]. MCT6 (SLC16A5) anspo s bume anide, bu
nei he L-lac ic acid o L- yp ophan, in a pH- and memb ane po en ial-sensi i e
bu in a non-p o on g adien -dependen manne [81]. MCT9 (SLC16A9)
polymo phism was ound o be associa ed wi h al e ed se um u ic acid [82]
howe e MCT9 subs a e is s ill unknown. Impo an ly, SLC16A12 (MCT12) has
been iden i ied as a possible bioma ke o colon, p os a e and b eas ca cinoma
due o gene hype me hyla ion [83] howe e he subs a e o MCT12 is s ill
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
19
unknown, as o he emaining membe s o he amily (MCT5, MCT7, MCT11,
MCT13 and MCT14).
Table 1 summa izes he cha ac e is ics o he human SLC16 amily o anspo e s
and Table 2 shows he subs a e a ini ies o he a ious MCT iso o ms in humans
and a s.
Table 1. The human SLC16 amily o anspo e s [47].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
20
Table 2. Compa ision o subs a e a ini ies o he a ious MCT iso o ms in human and a [47].
1.2.2 MCT Regula ion
Al hough he egula o y mechanisms o MCT exp ession a e a om being
comple ely unde s ood, e idence indica es ha MCTs migh be egula ed a
a ious poin s up o he unc ional p o ein. This includes bo h ansc ip ional and
pos - ansc ip ional le el [84-87] ha a ec s p o ein amoun s as well as egula o s
o anspo e ac i i y, like chape one p o eins. Ho mone egula ion has also been
desc ibed o MCTs, as well as egula ion by signaling pa hways like insulin-like
g ow h ac o ecep o ype I (IGF-IR) ac i a ion which up- egula es MCT1 [88].
MCT1 exp ession is pa icula ly mo e desc ibed han he o he iso o ms in di e en
physiological and pa hological condi ions. Repo s including MCT up- egula ion in
skele al muscle in esponse o aining [85, 89-96], down egula ion a e muscle
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
21
dene a ion and in lamma o y bowel diseases [97,98], changes in MCT exp ession
du ing de elopmen [99-103] o subs a e induced MCT1 up- egula ion [86, 87,
104] a e ela i ely equen . Howe e and impo an ly, egula o y mechanisms a y
among MCTs iso o ms, which allows induc ion o speci ic iso o ms upon di e en
s imuli, adap ing cells o di e en ene gy demands.
1.2.2.1 T ansc ip ional Le el
The analysis o SLC16A1 5’- lanking egion allowed he iden i ica ion o pu a i e
binding si e sequences o he ansc ip ion ac o s USF, nuclea ac o -kappaB
(NF-kB), ac i a ed p o ein 1 and 2 (AP1 and AP2) and s imula ing p o ein-1 (Sp1).
USF1 and USF2 ha e been desc ibed as po en ial ep esso p o eins o MCT1
[105] whe eas NF-kB pa hway has been in ol ed in he bu y a e-induced MCT1
up- egula ion [106]. AP2 has been associa ed o p o ein kinase C (PKC)-
dependen s imula ion o he SLC16A1 p omo e [107] .
Lac a e-induced inc ease in MCT1 has been linked o ac i a ion o NF-kB and
nuclea ac o e y h oid 2 (NF-E2) pa hways, as well as cAMP- esponse elemen -
binding p o ein (CREB) and NF-E2 ela ed ac o 2 (N 2) ansc ip ion ac o s, he
las h ee elemen s possessing also pu a i e ansc ip ion binding si es in he
SLC16A1 5’- lanking egion.
The co-ac i a o s pe oxisome p oli e a o -ac i a ed ecep o gamma, co-ac i a o
1 alpha (PGC-1a) [108] and pe oxisome p oli e a o -ac i a ed ecep o alpha
(PPAR) [109,110] ha e been associa ed wi h MCT1, bu no wi h MCT2 and
MCT4 up- egula ions. P omo e analyses o MCT1, MCT2 and MCT4 ha e shown
ha he SLC16A1 p omo e con ains wo pe oxisome p oli e a o -ac i a ed
ecep o esponse elemen s (PPRE) while SLC16A7 and SLC16A3 each con ain
one PPRE.
In exp ession s udies, SLC16A1 was also shown o be ac i a ed by c-myc and n-
myc p o o-oncogenes, while he p o-in lamma o y cy okines and TNF-a, ha e also
been implica ed in he ansc ip ional con ol o MCT1, by down- egula ing
SLC16A1 ansc ip ion [111-113].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
28
h ough he same anspo e s. Que ce in is also desc ibed as an inhibi o o he
monoca boxyla e anspo e iso o m 1 (MCT1). In p e ious s udies, i was
demons a ed ha Que ce in ac s as e e sible nonco alen inhibi o o L-lac a e
anspo by umou cells o ed blood cells [144, 145]. Mo e ecen ly, a s udy
aiming o cla i y he ole o la onoids in he modula ion o MCT1-media ed
anspo o hyd oxybu y a e in i o and in i o demons a ed ha Que ce in
(among o he s) is an e ec i e inhibi o o MCT1-media ed anspo [146].
Lonidamine is a de i a i e o indazole-3-ca boxylic acid, which o a long ime, has
been known o inhibi glycolysis in cance cells. Al hough his ac ion was o iginally
a ibu ed o hexokinase inhibi ion [147, 148], u he s udies e ealed ha
lonidamine inhibi s lac a e e lux om cance cells h ough inhibi ion o MCT1 and
MCT4 [149, 150]. Ac ually, despi e a lack o knowledge o i s p ecise mechanism
o ac ion, lonidamine has been e ec i e in clinical ials agains a ious umou s,
especially as a sensi ize o o he chemo he apies [151].
1.3 Monoca boxyla e T anspo e s in he Con ex o Cance
1.3.1 MCTs in human cance . Wha is desc ibed?
Rega ding cance esea ch, he e a e al eady se e al e idence o he
up egula ion o MCTs in se e al solid umou s, such as colo ec al ca cinomas
[152], u e ine ce ix ca cinomas [153], glioblas omas, b eas ca cinomas [154,
155] and lung umou s [156], poin ing o an impo an ole o his anspo e s in
he main enance o hese malignancies. The i s epo on MCT exp ession in
human umo samples desc ibed a dec ease o MCT1 exp ession in he colonic
ansi ion om no mali y o malignancy [157], which was u he suppo ed by a
la ge s udy [158]. In b eas cance , silencing o SLC16A1 by gene p omo e
hype me hyla ion was sugges ed in 4 o 20 b eas cance cases (20 %). In
con as , esul s om ou g oup showed a signi ican inc ease o MCT1
cy oplasmic and plasma memb ane exp ession in b eas ca cinoma, when
compa ing o no mal b eas epi helium [154]. MCT4 only showed a signi ican
inc ease in umo samples o cy oplasm exp ession, wi h no di e ences in plasma
memb ane exp ession. The li e a u e is also con o e sial in lung cance . A s udy

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
29
by Koukou akis and collabo a o s, no exp ession o MCTs in no mal lung was
ound, while exp ession o MCT1 was ound in all umo s examined and bo h
MCT2 and MCT4 we e also exp essed in cance cells. This s udy also analyzed
he possible me abolic coope a ion be ween lung cance cells and he umou -
associa ed s oma, howe e , umou associa ed s oma exp essed MCTs weakly
[15]. In opposi ion, a ecen s udy by ou g oup showed ha no mal lung p esen s
a high equency o MCT exp ession and, in ac , MCT4 is less exp essed in umo
samples han in no mal epi helium.
MCT exp ession has also been desc ibed in some gynecological umo s like
ce ical and o a ian cance [159]. In ce ical cance , a signi ican inc ease in
o e all and plasma memb ane exp ession o MCT1 and MCT4 was obse ed. In
o a ian cance , s aining o MCT1 and MCT4 as well as hei chape one CD147
was no ound in no mal o a ian issues and benign o a ian issues, while a ound
80 % o epi helial o a ian p ima y and me as a ic umo s showed exp ession o
hese p o eins. MCT1 was signi ican ly associa ed wi h low g ade umo s, high
FIGO s age, p esence o esidual umo , lack o elapse and p esence o asci es;
MCT4 was signi ican ly associa ed wi h high g ade umo s, high FIGO s age,
p esence o esidual umo , elapse and p esence o asci es. Impo an ly, MCT
exp ession was associa ed wi h he exp ession o he mul id ug esis ance
ma ke s MDR1 and MRP2. In con as o wha was ound in he p e ious ypes o
umou s, nei he MCT1 no MCT4 we e ound o be up- egula ed in gas ic
adenoca cinomas [160]. Ac ually, MCT4 exp ession was mo e equen ly obse ed
in no mal gas ic mucosa han in gas ic cance cells and e en less equen ly
obse ed in lymph-node me as asis, indica ing a p og essi e loss o his MCT
iso o m wi h disease p og ession. Table 3 shows an o e iew on MCT1 and MCT4
exp ession and he impac on p ognosis in di e en umou ypes.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
30
Table 3. O e iew o MCT1 and MCT4 exp ession and impac on p ognosis in di e en umou
ypes [57].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
31
O e all, he da a a ailable in he li e a u e suppo he hypo hesis o a majo ole o
MCTs in he eme gence o he hype -glycoly ic and acid- esis an pheno ypes, as
adap a ions o he hypoxic mic oen i onmen . The up- egula ion o MCTs in he
plasma memb ane o di e en ype o umo s is an adap i e mechanism o allow
con inuous high glycoly ic a es, by expo ing he accumula ing end-p oduc ,
lac a e, as well as o coun e ac acid-induced apop osis o nec osis. Howe e , i
was clea ha his migh no be he case o all umo ypes, he e o e, in mos
cases he e a e no unc ional s udies showing he dependence o he umo s on
MCT exp ession and ac i i y. As so, addi ional s udies on MCT exp ession in o he
umo ypes, con i ma ion o he esul s al eady published as well as addi ional
unc ional s udies a e needed o deeply unde s and he ole o MCTs in cance
main enance and agg essi eness and exac ly in which cases hese anspo e s
could be used o he apy.
1.3.2 MCTs as sui able a ge s o cance he apy. Wha is known?
La ely he e was an inc ease in he exploi a ion o ea men s ha a ge umou
me abolism, being some o hem al eady in clinical ial phase. Figu e 8 shows
ac ual and u u e he apeu ic a ge s o umou me abolism by a ge ing me abolic
enzymes.
Figu e 13. Ac ual and u u e he apeu ic a ge s (dashed lines) o umou me abolism by a ge ing
me abolic enzymes [161].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
32
Se e al s udies ha e al eady shown he in i o and in i o e ec o a ge ing
di e en MCTs iso o ms in human cance s.
I was demons a ed ha MCT inhibi ion dec eases in acellula pH [162], leads o
cell dea h and, impo an ly, enhances cance cell adiosensi i i y [163]. Resul s o
MCT4 show a dec ease in cance cell mig a ion, by mechanisms ha also in ol e
in e ac ion o MCT4 wi h β1-in eg in [164]. In con as , ano he s udy showed ha
silencing o MCT1 o MCT4 inhibi ed cance cell in asion, bu did no in luence cell
mig a ion [165]. In i o models ha e also been used, whe e adminis a ion o α-
cyano-4-hyd oxycinnamic acid (CHC), e a ded umo g ow h, ende ed umo
cells sensi i e o adia ion, induced umo nec osis and dec eased umo in asion
[166]. The impo ance o MCTs o in i o umo g ow h was con i med by a mo e
speci ic app oach, whe e combined silencing o MCT1 and MCT4 o silencing o
CD147 signi ican ly educed glycoly ic lux and umo g ow h. The e a e also o he
MCT inhibi o s desc ibed which a e ei he non-iso o m speci ic (ARC155858
a ge s bo h MCT1 and MCT2 [167] o a ge o he molecules besides MCTs (e.g.,
lonidamine p ima y a ge is hexokinase II)) [167,168]. Howe e , hese compounds
ha e been li le explo ed as lac a e anspo inhibi o s in he cance con ex . In
sum, i seems clea ha MCTs ep esen a sui able a ge o cance he apy;
howe e , he e ec o his inhibi ion seems highly dependen on he cell ype and
he iso o m ha is being a ge ed.
Figu e 14 shows he model o he apeu ic a ge ing o lac a e-based me abolic
symbiosis in umou s. I shows ha MCTs inhibi ion would ha e a majo e ec on
lac a e anspo , pH balance and umou homeos asis, by comp omising ae obic
glycolysis and mic oen i onmen al acidosis, as well as, he cell-cell lac a e shu le
be ween ae obic and hypoxic cell popula ions.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
33
Figu e 14. Model o he apeu ic a ge ing o lac a e-based me abolic symbiosis in umou s [118]
Rega ding p os a e cance , which is ou main ocus in his hesis, ew s udies exis
epo ing he e ec o MCTs inhibi ion in p os a e cance cells. As so, i is
impo an o in es in s udies e alua ing bo h blocking and he silencing o MCTs in
p os a e cance in o de o each a conclusion abou he e ec i eness o his
he apeu ic app oach.
1.4 P os a e Cance
1.4.1 Epidemiology o he disease
P os a e cance is one o he mos p e alen and inciden cance s in he male
popula ion wo ldwide a e lung cance , and he i h mos common cance o e all.
In Po ugal, p os a e cance is he leading cance among men wi h 5,140
es ima ed inciden cases in 2008 [169, 170]. The pa e ns o incidence
and mo ali y p o ide a numbe o in e es ing leads wi h peak incidences in he
Uni ed S a es, Aus alia and he Scandina ian coun ies. Incidence a es

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
34
in Asian coun ies a e gene ally low, bu in ecen yea s ha e isen p opo iona ely
mo e han in wes e n coun ies. Incidence a es inc eased d ama ically h ough he
ea ly 1990s [171].
In he la e 1970s and ea ly 1980s he e was a ise in incidence in pa , due o
inc eased de ec ion wi h mo e equen su gical ea men o benign p os a ic
hype plasia (BPH), pa icula ly, ansu e h al esec ion o he p os a e (TURP)
[172]. Be ween 1986 and 1992 he e was ano he sha p ise in incidence la gely
due o inc easing use o p os a e speci ic an igen (PSA) [173]. A ecen ly
published s udy poin s ou an inc ease o 26% in he incidence o PCa in he
pe iod be ween 1986 o 2005 in he Uni ed S a es, which means ha mo e han a
million addi ional men we e diagnosed wi h p os a e cance . Besides PSA
sc eening p og ammes, o he aspec s such as he in oduc ion o be e diagnos ic
ools like ans ec al ul asonog aphy (TRUS) –guided biopsy may be pa ially
esponsible o he inc eased incidence o p os a e cance in de eloped coun ies.
Howe e , sc eening p ac ice di e ences alone a e unlikely o explain he nea ly
huge di e ences in p os a e cance isk be ween high- and low- isk popula ions
[174, 175].
Despi e p os a e cance 's high mo bidi y, i s e iology emains obscu e, wi h he
only es ablished isk ac o s being inc easing age, ace, and a amily his o y. Many
pu a i e isk ac o s, including ho mones, die a y ac o s, obesi y, physical
inac i i y, occupa ion, asec omy, smoking, sexual ac o s, and gene ic
suscep ibili y, ha e been implica ed, bu he epidemiologic e idence is
inconclusi e. While i is no known whe he he isk ac o s explaining he obse ed
pa e ns a e en i onmen al, li es yle, o gene ic, i is likely ha a complex in e play
o hese ac o s is associa ed wi h p os a e cance de elopmen .
Conce ning mo ali y, he a es a e much less a iable han PCa incidence,
leading o a less accen ua ed di e ence be ween de eloped and de eloping
coun ies. Wi h he in oduc ion o PSA a sligh inc ease in mo ali y a es was
obse ed bu his inc ease was e i ied bo h in high and low isk coun ies [176].
The easons o his ime ends in mo ali y a es a e s ill con o e sial bu he
in oduc ion o he PSA sc eening was in ce ain way esponsible o he
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
35
inc easing a es due o misce i ica ion o cause o dea h among men diagnosed
wi h la en umou s, howe e i may also play a ole in dec easing a es because o
an ea lie diagnosis o mos o he cases.
Ea ly de ec ion in p os a e cance is c ucial since only o gan-con ined disease is
amenable o cu a i e ea men whe eas pa ien s wi h ad anced disease can only
be pallia ed. Al hough he e a e some a ailable ools equen ly used o PCa
de ec ion, hei pe o mance is sub-op imal due o non-sa is ac o y sensi i i y and
speci ici y a es. In his con ex , new bioma ke s a e u gen ly needed, no only o
ea ly de ec ion bu also as ancilla y ools o diagnosis, which is s ill based on
his opa hological e alua ion o biopsy specimens.
1.4.2 P os a e Cance Diagnosis
Usually, men wi h PSA le els o 4.0 ng/mL o g ea e a e candida es o pe o m a
p os a ic co e needle biopsy [177]. This cu o alue o he PSA es is s ill
con o e sial because PSA le el sc eening p oduces alse-nega i e o alse-
posi i e esul s ha can lead men wi hou disease o be submi ed o unnecessa y
addi ional es ing [177, 178]. Impo an ly, PSA le els sc eening a e no accep able
diagnos ic ools o PCa in ou ine clinical p ac ice because hey lack adequa e
sensi i i y and speci ici y. Rega dless he u ili y o diagnosis aid- ools, he only way
o access diagnosis o p os a e cance is by his opa hological analysis o p os a ic
issue ob ained om biopsy o p os a ec omy specimens. I is c ucial o pe o m a
p ope his opa hological e alua ion o he issue collec ed om he pa ien in o de
o de e mine which a e he bes ea men op ions a ailable o each pa ien
because he combina ion o his e alua ion esul s wi h o he pa ame e s, such as
se um PSA le els, in nomog ams do ha e p ognos ic impac [179]. Biopsy
echniques ha e been imp o ed in o de o educe mo bidi y and inc ease he a e
and accu acy o de ec ion in he i s biopsy, al hough he op imal numbe o co es
ha mus be collec ed is s ill a ma e o deba e [178].
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
36
1.4.2.1 His opha ological e alua ion. The Gleason sco e sys em o p os a e
cance g ading
The Gleason g ading sys em was i s ly desc ibed in 1996 and i is p esen ly, wi h
some modi ica ions, he mos commonly used me hod o p os a e cance g ading.
Because he Gleason sco e (GS) is di ec ly co ela ed wi h PCa p ognosis, i s
accu a e e alua ion is c i ical o he na u al his o y o he disease o he isk o
ecu ence ollowing adical p os a ec omy o adio he apy [180].
The sys em is based on he e alua ion o he glandula a chi ec u al pa e ns o
he umou issue, ecognizing i e di e en g ades ha ange om good o poo
g ade o di e en ia ion. Because p os a e adenoca cinomas a e he e ogeneous,
mo e han one o he i e pa e ns de ined by Gleason migh be p esen in he
same umou . To inco po a e his he e ogenei y in umou g ading, he Gleason
sco e (GS) was de eloped, esul ing om he sum o wo mos p edominan
cance pa e n (g ades) in a sample. GS a ies om 2 (1+1) o 10 (5+5) (Figu e
15).
Figu e 15. Upda ed Gleason sco e o his ological g ading
o p os a e umou s [181] .
Pa e n 1- Closely packed small, uni o m glands.
Pa e n 2- Mo e s oma be ween he glands ha a e ound
o o al wi h smoo h ends and may minimally in ade non-
neoplas ic issue.
Pa e n 3- I egula size glands wi h angula shape and
mo e in il a i e ma gins.
Pa e n 4- Fused, c ibi o m o poo ly de ined glands.
Pa e n 5- Only occasional gland o ma ion.
1.4.2.2 Clinical and Pa hological S aging
Ano he aspec ha helps o p edic he p og ession o PCa is he s aging which
comp ises in o ma ion abou he ex ension o he disease (local, egional o
sys emic) and i is widely classi ied using he UICC (In e na ional Union agains
Cance ) Tumou Node Me as asis (TNM) sys em (Table 4). In his classi ica ion, T
ep esen s he ex en o he p ima y umou , N he lymph node s a us and M o
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
37
dis an me as asis. The clinical s age is based on he e alua ion o he pa ien by
digi al ec al exam (DRE), ans ec al ul asonog aphy (TRUS), and, possibly,
magne ic esonance imaging (MRI) [178,182,183] . Fu he in o ma ion can be
p o ided by biopsy his opa hological e alua ion and se um PSA le els [188].
Al e na i ely, pa hological s age is de e mined a e su gical emo al o he
p os a e h ough adequa e analysis o he p os a ec omy specimen, and i p edic s
disease ecu ence much mo e accu a ely [183]. The e a e se e al independen
p ognos ic ac o s included in s aging ha a e impo an o guide clinical decisions
conce ning he ea men op ions. These a e ex a-p os a ic umou in asion,
seminal esicles in ol emen , lymph node me as asis and dis an me as asis.
These ea u es ha e been combined in nomog ams wi h o he p ognos ic ac o s,
such as p eope a i e se um PSA le els, GS in he p os a ec omy specimen and
su gical ma gins s a us in an a emp o e ine he p edic ion o p ognosis
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
44
21. Semenza, G.L., Hypoxia-inducible ac o 1: mas e egula o o O2
homeos asis. Cu Opin Gene De , 1998. 8(5): p. 588-94.
22. Semenza, G.L., Regula ion o mammalian O2 homeos asis by hypoxia-
inducible ac o 1. Annu Re Cell De Biol, 1999. 15: p. 551-78.
23. Semenza, G.L., Hypoxia, clonal selec ion, and he ole o HIF-1 in umo
p og ession. C i Re Biochem Mol Biol, 2000. 35(2): p. 71-103.
24. Semenza, G.L., Hypoxia-inducible ac o 1: con ol o oxygen homeos asis
in heal h and disease. Pedia Res, 2001. 49(5): p. 614-7.
25. G eije , A.E., e al., Up- egula ion o gene exp ession by hypoxia is
media ed p edominan ly by hypoxia-inducible ac o 1 (HIF-1). J Pa hol,
2005. 206(3): p. 291-304.
26. Cassa augh, J. and K.M. Lounsbu y, Hypoxia-media ed biological con ol. J
Cell Biochem, 2011. 112(3): p. 735-44.
27. Chiche, J., M.C. B ahimi-Ho n, and J. Pouyssegu , Tumou hypoxia induces
a me abolic shi causing acidosis: a common ea u e in cance . J Cell Mol
Med, 2010. 14(4): p. 771-94.
28. Gillies, R.J., I. Robey, and R.A. Ga enby, Causes and consequences o
inc eased glucose me abolism o cance s. J Nucl Med, 2008. 49 Suppl 2:
p. 24S-42S.
29. Ha is, A.L., Hypoxia--a key egula o y ac o in umou g ow h. Na Re
Cance , 2002. 2(1): p. 38-47.
30. Pas o eko a, S., P.J. Ra cli e, and J. Pas o ek, Molecula mechanisms o
ca bonic anhyd ase IX-media ed pH egula ion unde hypoxia. BJU In ,
2008. 101 Suppl 4: p. 8-15.
31. Po po a o, P.E., e al., An icance a ge s in he glycoly ic me abolism o
umo s: a comp ehensi e e iew. F on Pha macol, 2011. 2: p. 49.
32. Quenne , V., e al., Tumo lac a e con en p edic s o esponse o
ac iona ed i adia ion o human squamous cell ca cinomas in nude mice.
Radio he Oncol, 2006. 81(2): p. 130-5.
33. B izel, D.M., e al., Ele a ed umo lac a e concen a ions p edic o an
inc eased isk o me as ases in head-and-neck cance . In J Radia Oncol
Biol Phys, 2001. 51(2): p. 349-53.
34. Paschen, W., e al., Lac a e and pH in he b ain: associa ion and
dissocia ion in di e en pa hophysiological s a es. J Neu ochem, 1987.
48(1): p. 154-9.
35. Walen a, S., T. Sch oede , and W. Muelle -Kliese , Me abolic mapping wi h
bioluminescence: basic and clinical ele ance. Biomol Eng, 2002. 18(6): p.
249-62.
36. Kuma , V.B., e al., Endo helial cell esponse o lac a e: implica ion o PAR
modi ica ion o VEGF. J Cell Physiol, 2007. 211(2): p. 477-85.
37. S e n, R., e al., Lac a e s imula es ib oblas exp ession o hyalu onan and
CD44: he Wa bu g e ec e isi ed. Exp Cell Res, 2002. 276(1): p. 24-31.
38. Rud abha la, S.R., C.L. Maha ey, and M.E. Mumme , Tumo
mic oen i onmen modula es hyalu onan exp ession: he lac a e e ec . J
In es De ma ol, 2006. 126(6): p. 1378-87.
39. Baumann, F., e al., Lac a e p omo es glioma mig a ion by TGF-be a2-
dependen egula ion o ma ix me allop o einase-2. Neu o Oncol, 2009.
11(4): p. 368-80.
40. Mazu ek, S., e al., Tumo M2-PK and glu aminoly ic enzymes in he
me abolic shi o umo cells. An icance Res, 2000. 20(6D): p. 5151-4.

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
45
41. DeBe a dinis, R.J., e al., Beyond ae obic glycolysis: ans o med cells can
engage in glu amine me abolism ha exceeds he equi emen o p o ein
and nucleo ide syn hesis. P oc Na l Acad Sci U S A, 2007. 104(49): p.
19345-50.
42. Juel, C. and A.P. Hales ap, Lac a e anspo in skele al muscle - ole and
egula ion o he monoca boxyla e anspo e . J Physiol, 1999. 517 ( P 3):
p. 633-42.
43. Hales ap, A.P. and R.M. Den on, Speci ic inhibi ion o py u a e anspo in
a li e mi ochond ia and human e y h ocy es by alpha-cyano-4-
hyd oxycinnama e. Biochem J, 1974. 138(2): p. 313-6.
44. Juel, C. and A.P. Hales ap, Lac a e anspo in skele al muscle - ole and
egula ion o he monoca boxyla e anspo e . J Physiol, 1999. 517 ( P 3):
p. 633-42.
45. Hales ap, A.P. and N.T. P ice, The p o on-linked monoca boxyla e
anspo e (MCT) amily: s uc u e, unc ion and egula ion. Biochem J,
1999. 343 P 2: p. 281-99.
46. Juel, C., Lac a e-p o on co anspo in skele al muscle. Physiol Re , 1997.
77(2): p. 321-58.
47. Hales ap, A.P. and D. Me edi h, The SLC16 gene amily- om
monoca boxyla e anspo e s (MCTs) o a oma ic amino acid anspo e s
and beyond. P luge s A ch, 2004. 447(5): p. 619-28.
48. P ice, N.T., V.N. Jackson, and A.P. Hales ap, Cloning and sequencing o
ou new mammalian monoca boxyla e anspo e (MCT) homologues
con i ms he exis ence o a anspo e amily wi h an ancien pas . Biochem
J, 1998. 329 ( P 2): p. 321-8.
49. Ca pen e , L., R.C. Poole, and A.P. Hales ap, Cloning and sequencing o
he monoca boxyla e anspo e om mouse Eh lich Le e umou cell
con i ms i s iden i y as MCT1 and demons a es ha glycosyla ion is no
equi ed o MCT1 unc ion. Biochim Biophys Ac a, 1996. 1279(2): p. 157-
63.
50. Yoon, H., e al., Iden i ica ion o a unique monoca boxyla e anspo e
(MCT3) in e inal pigmen epi helium. Biochem Biophys Res Commun,
1997. 234(1): p. 90-4.
51. Yoon, H. and N.J. Philp, Genomic s uc u e and de elopmen al exp ession
o he chicken nonoca boxyla e anspo e MCT3 gene. Exp Eye Res,
1998. 67(4): p. 417-24.
52. de B uijne, A.W., H. V eebu g, and J. an S e eninck, Al e na i e-subs a e
inhibi ion o L-lac a e anspo ia he monoca boxyla e-speci ic ca ie
sys em in human e y h ocy es. Biochim Biophys Ac a, 1985. 812(3): p. 841-
4.
53. Lin, R.Y., e al., Human monoca boxyla e anspo e 2 (MCT2) is a high
a ini y py u a e anspo e . J Biol Chem, 1998. 273(44): p. 28959-65.
54. Dimme , K.S., e al., The low-a ini y monoca boxyla e anspo e MCT4 is
adap ed o he expo o lac a e in highly glycoly ic cells. Biochem J, 2000.
350 P 1: p. 219-27.
55. De B uijne, A.W., H. V eebu g, and J. Van S e eninck, Kine ic analysis o L-
lac a e anspo in human e y h ocy es ia he monoca boxyla e-speci ic
ca ie sys em. Biochim Biophys Ac a, 1983. 732(3): p. 562-8.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
46
56. Philp, N.J., H. Yoon, and E.F. G ollman, Monoca boxyla e anspo e
MCT1 is loca ed in he apical memb ane and MCT3 in he basal memb ane
o a RPE. Am J Physiol, 1998. 274(6 P 2): p. R1824-8.
57. Pinhei o, C., e al., Role o monoca boxyla e anspo e s in human
cance s: s a e o he a . J Bioene g Biomemb , 2012. 44(1): p. 127-39.
58. Philp, N.J., e al., Loss o MCT1, MCT3, and MCT4 exp ession in he e inal
pigmen epi helium and neu al e ina o he 5A11/basigin-null mouse. In es
Oph halmol Vis Sci, 2003. 44(3): p. 1305-11.
59. Cu , M.A. and S.P. Shi azi-Beechey, The human monoca boxyla e
anspo e , MCT1: genomic o ganiza ion and p omo e analysis. Biochem
Biophys Res Commun, 2002. 292(4): p. 1048-56.
60. Fishbein, W.N., N. Me ezhinskaya, and J.W. Foellme , Rela i e dis ibu ion
o h ee majo lac a e anspo e s in ozen human issues and hei
localiza ion in un ixed skele al muscle. Muscle Ne e, 2002. 26(1): p. 101-
12.
61. Hashimo o, T., R. Hussien, and G.A. B ooks, Colocaliza ion o MCT1,
CD147, and LDH in mi ochond ial inne memb ane o L6 muscle cells:
e idence o a mi ochond ial lac a e oxida ion complex. Am J Physiol
Endoc inol Me ab, 2006. 290(6): p. E1237-44.
62. Yoshida, Y., e al., Negligible di ec lac a e oxida ion in subsa colemmal and
in e myo ib illa mi ochond ia ob ained om ed and whi e a skele al
muscle. J Physiol, 2007. 582(P 3): p. 1317-35.
63. McClelland, G.B., e al., Pe oxisomal memb ane monoca boxyla e
anspo e s: e idence o a edox shu le sys em? Biochem Biophys Res
Commun, 2003. 304(1): p. 130-5.
64. Jackson, V.N., e al., Cloning o he monoca boxyla e anspo e iso o m
MCT2 om a es is p o ides e idence ha exp ession in issues is
species-speci ic and may in ol e pos - ansc ip ional egula ion. Biochem J,
1997. 324 ( P 2): p. 447-53.
65. Ga cia, C.K., e al., cDNA cloning o MCT2, a second monoca boxyla e
anspo e exp essed in di e en cells han MCT1. J Biol Chem, 1995.
270(4): p. 1843-9.
66. Ge ha , D.Z., R.L. Leino, and L.R. D ewes, Dis ibu ion o monoca boxyla e
anspo e s MCT1 and MCT2 in a e ina. Neu oscience, 1999. 92(1): p.
367-75.
67. Pie e, K., e al., Cell-speci ic localiza ion o monoca boxyla e anspo e s,
MCT1 and MCT2, in he adul mouse b ain e ealed by double
immunohis ochemical labeling and con ocal mic oscopy. Neu oscience,
2000. 100(3): p. 617-27.
68. Pie e, K., P.J. Magis e i, and L. Pelle in, MCT2 is a majo neu onal
monoca boxyla e anspo e in he adul mouse b ain. J Ce eb Blood Flow
Me ab, 2002. 22(5): p. 586-95.
69. B oe , S., e al., Cha ac e iza ion o he high-a ini y monoca boxyla e
anspo e MCT2 in Xenopus lae is oocy es. Biochem J, 1999. 341 ( P 3):
p. 529-35.
70. Debe na di, R., e al., Cell-speci ic exp ession pa e n o monoca boxyla e
anspo e s in as ocy es and neu ons obse ed in di e en mouse b ain
co ical cell cul u es. J Neu osci Res, 2003. 73(2): p. 141-55.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
47
71. Pelle in, L., e al., Cellula and subcellula dis ibu ion o monoca boxyla e
anspo e s in cul u ed b ain cells and in he adul b ain. J Neu osci Res,
2005. 79(1-2): p. 55-64.
72. Ben on, C.R., e al., Monoca boxyla e anspo e s in subsa colemmal and
in e myo ib illa mi ochond ia. Biochem Biophys Res Commun, 2004.
323(1): p. 249-53.
73. Manning Fox, J.E., D. Me edi h, and A.P. Hales ap, Cha ac e isa ion o
human monoca boxyla e anspo e 4 subs an ia es i s ole in lac ic acid
e lux om skele al muscle. J Physiol, 2000. 529 P 2: p. 285-93.
74. F iesema, E.C., e al., Iden i ica ion o monoca boxyla e anspo e 8 as a
speci ic hy oid ho mone anspo e . J Biol Chem, 2003. 278(41): p. 40128-
35.
75. F iesema, E.C., e al., E ec i e cellula up ake and e lux o hy oid
ho mone by human monoca boxyla e anspo e 10. Mol Endoc inol, 2008.
22(6): p. 1357-69.
76. F iesema, E.C., e al., Associa ion be ween mu a ions in a hy oid ho mone
anspo e and se e e X-linked psychomo o e a da ion. Lance , 2004.
364(9443): p. 1435-7.
77. Dumi escu, A.M., e al., A no el synd ome combining hy oid and
neu ological abno mali ies is associa ed wi h mu a ions in a
monoca boxyla e anspo e gene. Am J Hum Gene , 2004. 74(1): p. 168-
75.
78. B ockmann, K., e al., X-linked pa oxysmal dyskinesia and se e e global
e a da ion caused by de ec i e MCT8 gene. J Neu ol, 2005. 252(6): p. 663-
6.
79. Boccone, L., e al., Allan-He ndon-Dudley synd ome (AHDS) in wo
consecu i e gene a ions caused by a missense MCT8 gene mu a ion.
Pheno ypic a iabili y wi h he p esence o no mal se um T3 le els. Eu J
Med Gene , 2013. 56(4): p. 207-10.
80. Ma anduba, C.M., e al., Dec eased cellula up ake and me abolism in
Allan-He ndon-Dudley synd ome (AHDS) due o a no el mu a ion in he
MCT8 hy oid ho mone anspo e . J Med Gene , 2006. 43(5): p. 457-60.
81. Mu akami, Y., e al., Func ional cha ac e iza ion o human monoca boxyla e
anspo e 6 (SLC16A5). D ug Me ab Dispos, 2005. 33(12): p. 1845-51.
82. Kolz, M., e al., Me a-analysis o 28,141 indi iduals iden i ies common
a ian s wi hin i e new loci ha in luence u ic acid concen a ions. PLoS
Gene , 2009. 5(6): p. e1000504.
83. Chung, W., e al., Iden i ica ion o no el umo ma ke s in p os a e, colon
and b eas cance by unbiased me hyla ion p o iling. PLoS One, 2008. 3(4):
p. e2079.
84. Mo is, M.E. and M.A. Felmlee, O e iew o he p o on-coupled MCT
(SLC16A) amily o anspo e s: cha ac e iza ion, unc ion and ole in he
anspo o he d ug o abuse gamma-hyd oxybu y ic acid. AAPS J, 2008.
10(2): p. 311-21.
85. Bonen, A., e al., Abundance and subcellula dis ibu ion o MCT1 and
MCT4 in hea and as - wi ch skele al muscles. Am J Physiol Endoc inol
Me ab, 2000. 278(6): p. E1067-77.
86. Coles, L., e al., Exe cise apidly inc eases exp ession o he
monoca boxyla e anspo e s MCT1 and MCT4 in a muscle. J Physiol,
2004. 561(P 1): p. 253-61.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
48
87. Cu , M.A., D.W. Lambe , and S.P. Shi azi-Beechey, Subs a e-induced
egula ion o he human colonic monoca boxyla e anspo e , MCT1. J
Physiol, 2002. 539(P 2): p. 361-71.
88. Hashimo o, T., e al., Lac a e sensi i e ansc ip ion ac o ne wo k in L6
cells: ac i a ion o MCT1 and mi ochond ial biogenesis. FASEB J, 2007.
21(10): p. 2602-12.
89. Kang, K.W., M.J. Jin, and H.K. Han, IGF-I ecep o gene ac i a ion
enhanced he exp ession o monoca boxylic acid anspo e 1 in
hepa oca cinoma cells. Biochem Biophys Res Commun, 2006. 342(4): p.
1352-5.
90. Bake , S.K., K.J. McCullagh, and A. Bonen, T aining in ensi y-dependen
and issue-speci ic inc eases in lac a e up ake and MCT-1 in hea and
muscle. J Appl Physiol, 1998. 84(3): p. 987-94.
91. Pilegaa d, H., e al., E ec o high-in ensi y exe cise aining on lac a e/H+
anspo capaci y in human skele al muscle. Am J Physiol, 1999. 276(2 P
1): p. E255-61.
92. Dubouchaud, H., e al., Endu ance aining, exp ession, and physiology o
LDH, MCT1, and MCT4 in human skele al muscle. Am J Physiol Endoc inol
Me ab, 2000. 278(4): p. E571-9.
93. G een, H., e al., Inc eases in muscle MCT a e associa ed wi h educ ions
in muscle lac a e a e a single exe cise session in humans. Am J Physiol
Endoc inol Me ab, 2002. 282(1): p. E154-60.
94. Juel, C., e al., E ec o high-in ensi y in e mi en aining on lac a e and H+
elease om human skele al muscle. Am J Physiol Endoc inol Me ab, 2004.
286(2): p. E245-51.
95. Thomas, C., e al., Monoca boxyla e anspo e s, blood lac a e emo al
a e sup amaximal exe cise, and a igue indexes in humans. J Appl
Physiol, 2005. 98(3): p. 804-9.
96. Bu gomas e , K.A., e al., Di e gen esponse o me aboli e anspo
p o eins in human skele al muscle a e sp in in e al aining and
de aining. Am J Physiol Regul In eg Comp Physiol, 2007. 292(5): p.
R1970-6.
97. Moh , M., e al., E ec o wo di e en in ense aining egimens on skele al
muscle ion anspo p o eins and a igue de elopmen . Am J Physiol Regul
In eg Comp Physiol, 2007. 292(4): p. R1594-602.
98. Thibaul , R., e al., Down- egula ion o he monoca boxyla e anspo e 1 is
in ol ed in bu y a e de iciency du ing in es inal in lamma ion.
Gas oen e ology, 2007. 133(6): p. 1916-27.
99. Ra iki, A., e al., Highly di e en ial exp ession o he monoca boxyla e
anspo e s MCT2 and MCT4 in he de eloping a b ain. Neu oscience,
2003. 122(3): p. 677-88.
100. Leino, R.L., D.Z. Ge ha , and L.R. D ewes, Monoca boxyla e anspo e
(MCT1) abundance in b ains o suckling and adul a s: a quan i a i e
elec on mic oscopic immunogold s udy. B ain Res De B ain Res, 1999.
113(1-2): p. 47-54.
101. Ha a, H., e al., Tissue-speci ic and iso o m-speci ic changes in MCT1 and
MCT4 in hea and soleus muscle du ing a 1-y pe iod. Am J Physiol
Endoc inol Me ab, 2001. 281(4): p. E749-56.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
49
102. Okamu a, H., S.S. Spice , and B.A. Schul e, De elopmen al exp ession o
monoca boxyla e anspo e in he ge bil inne ea . Neu oscience, 2001.
107(3): p. 499-505.
103. Baud, O., e al., Pe ina al and ea ly pos na al changes in he exp ession o
monoca boxyla e anspo e s MCT1 and MCT2 in he a o eb ain. J Comp
Neu ol, 2003. 465(3): p. 445-54.
104. Leino, R.L., e al., Die -induced ke osis inc eases monoca boxyla e
anspo e (MCT1) le els in a b ain. Neu ochem In , 2001. 38(6): p. 519-
27.
105. Hadjiagapiou, C., e al., Role o USF1 and USF2 as po en ial ep esso
p o eins o human in es inal monoca boxyla e anspo e 1 p omo e . Am J
Physiol Gas oin es Li e Physiol, 2005. 288(6): p. G1118-26.
106. Bo haku , A., e al., Regula ion o monoca boxyla e anspo e 1 (MCT1)
p omo e by bu y a e in human in es inal epi helial cells: in ol emen o NF-
kappaB pa hway. J Cell Biochem, 2008. 103(5): p. 1452-63.
107. Saksena, S., e al., PKC-dependen s imula ion o he human MCT1
p omo e in ol es ansc ip ion ac o AP2. Am J Physiol Gas oin es Li e
Physiol, 2009. 296(2): p. G275-83.
108. Ben on, C.R., e al., PGC-1alpha inc eases skele al muscle lac a e up ake
by inc easing he exp ession o MCT1 bu no MCT2 o MCT4. Physiol
Genomics, 2008. 35(1): p. 45-54.
109. Konig, B., e al., Monoca boxyla e anspo e (MCT)-1 is up- egula ed by
PPARalpha. Biochim Biophys Ac a, 2008. 1780(6): p. 899-904.
110. Konig, B., e al., Monoca boxyla e anspo e 1 and CD147 a e up-
egula ed by na u al and syn he ic pe oxisome p oli e a o -ac i a ed
ecep o alpha agonis s in li e s o oden s and pigs. Mol Nu Food Res,
2010. 54(9): p. 1248-56.
111. Colle , H.A., e al., Exp ession analysis wi h oligonucleo ide mic oa ays
e eals ha MYC egula es genes in ol ed in g ow h, cell cycle, signaling,
and adhesion. P oc Na l Acad Sci U S A, 2000. 97(7): p. 3260-5.
112. Fang, J., e al., The H+-linked monoca boxyla e anspo e
(MCT1/SLC16A1): a po en ial he apeu ic a ge o high- isk
neu oblas oma. Mol Pha macol, 2006. 70(6): p. 2108-15.
113. Kang, K.W., e al., C-myc ampli ica ion al e ed he gene exp ession o ABC-
and SLC- anspo e s in human b eas epi helial cells. Mol Pha m, 2009.
6(2): p. 627-33.
114. McClelland, G.B. and G.A. B ooks, Changes in MCT 1, MCT 4, and LDH
exp ession a e issue speci ic in a s a e long- e m hypoba ic hypoxia. J
Appl Physiol, 2002. 92(4): p. 1573-84.
115. Zhang, F., e al., Monoca boxyla e anspo e exp ession in he
spon aneous hype ensi e a : e ec o s oke. J Neu osci Res, 2005. 79(1-
2): p. 139-45.
116. O d, J.J., e al., Compa ison o hypoxia ansc ip ome in i o wi h in i o
gene exp ession in human bladde cance . B J Cance , 2005. 93(3): p.
346-54.
117. Kay, H.H., S. Zhu, and S. Tsoi, Hypoxia and lac a e p oduc ion in
ophoblas cells. Placen a, 2007. 28(8-9): p. 854-60.
118. Son eaux, P., e al., Ta ge ing lac a e- ueled espi a ion selec i ely kills
hypoxic umo cells in mice. J Clin In es , 2008. 118(12): p. 3930-42.

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
50
119. Pe ez de He edia, F., I.S. Wood, and P. T ayhu n, Hypoxia s imula es
lac a e elease and modula es monoca boxyla e anspo e (MCT1, MCT2,
and MCT4) exp ession in human adipocy es. P luge s A ch, 2010. 459(3):
p. 509-18.
120. P oud, C.G., Regula ion o mRNA ansla ion. Essays Biochem, 2001. 37:
p. 97-108.
121. Li, K.K., e al., miR-124 is equen ly down- egula ed in medulloblas oma
and is a nega i e egula o o SLC16A1. Hum Pa hol, 2009. 40(9): p. 1234-
43.
122. Wilson, M.C., e al., Basigin (CD147) is he a ge o o ganome cu ial
inhibi ion o monoca boxyla e anspo e iso o ms 1 and 4: he ancilla y
p o ein o he insensi i e MCT2 is EMBIGIN (gp70). J Biol Chem, 2005.
280(29): p. 27213-21.
123. Deo a, A.A., e al., Mechanisms egula ing issue-speci ic pola i y o
monoca boxyla e anspo e s and hei chape one CD147 in kidney and
e inal epi helia. P oc Na l Acad Sci U S A, 2005. 102(45): p. 16245-50.
124. Biswas, C., e al., The human umo cell-de i ed collagenase s imula o y
ac o ( enamed EMMPRIN) is a membe o he immunoglobulin
supe amily. Cance Res, 1995. 55(2): p. 434-9.
125. Wilson, M.C., D. Me edi h, and A.P. Hales ap, Fluo escence esonance
ene gy ans e s udies on he in e ac ion be ween he lac a e anspo e
MCT1 and CD147 p o ide in o ma ion on he opology and s oichiome y o
he complex in si u. J Biol Chem, 2002. 277(5): p. 3666-72.
126. Slomiany, M.G., e al., Hyalu onan, CD44, and emmp in egula e lac a e
e lux and memb ane localiza ion o monoca boxyla e anspo e s in
human b eas ca cinoma cells. Cance Res, 2009. 69(4): p. 1293-301.
127. Buyse, M., e al., Luminal lep in enhances CD147/MCT-1-media ed up ake
o bu y a e in he human in es inal cell line Caco2-BBE. J Biol Chem, 2002.
277(31): p. 28182-90.
128. Pie e, K., e al., No ad enaline enhances monoca boxyla e anspo e 2
exp ession in cul u ed mouse co ical neu ons ia a ansla ional egula ion.
J Neu ochem, 2003. 86(6): p. 1468-76.
129. Wang, Y., e al., T3 inc eases lac a e anspo and he exp ession o
MCT4, bu no MCT1, in a skele al muscle. Am J Physiol Endoc inol
Me ab, 2003. 285(3): p. E622-8.
130. Fanelli, A., e al., MCT1 and i s accesso y p o ein CD147 a e di e en ially
egula ed by TSH in a hy oid cells. Am J Physiol Endoc inol Me ab, 2003.
285(6): p. E1223-9.
131. Saksena, S., e al., Mechanisms unde lying modula ion o monoca boxyla e
anspo e 1 (MCT1) by soma os a in in human in es inal epi helial cells.
Am J Physiol Gas oin es Li e Physiol, 2009. 297(5): p. G878-85.
132. Mu ay, C.M., e al., Monoca boxyla e anspo e MCT1 is a a ge o
immunosupp ession. Na Chem Biol, 2005. 1(7): p. 371-6.
133. Guile, S.D., e al., Po en blocke s o he monoca boxyla e anspo e
MCT1: no el immunomodula o y compounds. Bioo g Med Chem Le , 2006.
16(8): p. 2260-5.
134. Da is, C.D. and J.A. Milne , Bioma ke s o die and cance p e en ion
esea ch: po en ials and challenges. Ac a Pha macol Sin, 2007. 28(9): p.
1262-73.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
51
135. Nade i, G.A., e al., An i-oxidan e ec o la onoids on he suscep ibili y o
LDL oxida ion. Mol Cell Biochem, 2003. 246(1-2): p. 193-6.
136. Mamani-Ma suda, M., e al., The apeu ic and p e en i e p ope ies o
que ce in in expe imen al a h i is co ela e wi h dec eased mac ophage
in lamma o y media o s. Biochem Pha macol, 2006. 72(10): p. 1304-10.
137. Lo i o, S.B. and B. F ei, Die a y la onoids a enua e umo nec osis ac o
alpha-induced adhesion molecule exp ession in human ao ic endo helial
cells. S uc u e- unc ion ela ionships and ac i i y a e i s pass
me abolism. J Biol Chem, 2006. 281(48): p. 37102-10.
138. Pian elli, M., e al., Fla onoids inhibi melanoma lung me as asis by
impai ing umo cells endo helium in e ac ions. J Cell Physiol, 2006. 207(1):
p. 23-9.
139. Vijayababu, M.R., e al., Que ce in down egula es ma ix
me allop o einases 2 and 9 p o eins exp ession in p os a e cance cells
(PC-3). Mol Cell Biochem, 2006. 287(1-2): p. 109-16.
140. Tan, W.F., e al., Que ce in, a die a y-de i ed la onoid, possesses
an iangiogenic po en ial. Eu J Pha macol, 2003. 459(2-3): p. 255-62.
141. Cunningham, P., I. A zal-Ahmed, and R.J. Na alin, Docking s udies show
ha D-glucose and que ce in slide h ough he anspo e GLUT1. J Biol
Chem, 2006. 281(9): p. 5797-803.
142. S obel, P., e al., My ice in, que ce in and ca echin-galla e inhibi glucose
up ake in isola ed a adipocy es. Biochem J, 2005. 386(P 3): p. 471-8.
143. Pa k, J.B. and M. Le ine, In acellula accumula ion o asco bic acid is
inhibi ed by la onoids ia blocking o dehyd oasco bic acid and asco bic
acid up akes in HL-60, U937 and Ju ka cells. J Nu , 2000. 130(5): p. 1297-
302.
144. Bel , J.A., e al., Inhibi ion o lac a e anspo and glycolysis in Eh lich
asci es umo cells by bio la onoids. Biochemis y, 1979. 18(16): p. 3506-
11.
145. Deu icke, B., Monoca boxyla e anspo in ed blood cells: kine ics and
chemical modi ica ion. Me hods Enzymol, 1989. 173: p. 300-29.
146. Wang, Q. and M.E. Mo is, Fla onoids modula e monoca boxyla e
anspo e -1-media ed anspo o gamma-hyd oxybu y a e in i o and in
i o. D ug Me ab Dispos, 2007. 35(2): p. 201-8.
147. Flo idi, A., e al., Lonidamine, a selec i e inhibi o o ae obic glycolysis o
mu ine umo cells. J Na l Cance Ins , 1981. 66(3): p. 497-9.
148. Pulselli, R., e al., E ec o lonidamine on he mi ochond ial po en ial in si u
in Eh lich asci es umo cells. An icance Res, 1996. 16(1): p. 419-23.
149. Ben-Ho in, H., e al., Mechanism o ac ion o he an ineoplas ic d ug
lonidamine: 31P and 13C nuclea magne ic esonance s udies. Cance
Res, 1995. 55(13): p. 2814-21.
150. Ben-Yoseph, O., e al., Mechanism o ac ion o lonidamine in he 9L b ain
umo model in ol es inhibi ion o lac a e e lux and in acellula
acidi ica ion. J Neu ooncol, 1998. 36(2): p. 149-57.
151. Di Cosimo, S., e al., Lonidamine: e icacy and sa e y in clinical ials o he
ea men o solid umo s. D ugs Today (Ba c), 2003. 39(3): p. 157-74.
152. Pinhei o, C., e al., Inc eased exp ession o monoca boxyla e anspo e s
1, 2, and 4 in colo ec al ca cinomas. Vi chows A ch, 2008. 452(2): p. 139-
46.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
52
153. Pinhei o, C., e al., Inc easing exp ession o monoca boxyla e anspo e s
1 and 4 along p og ession o in asi e ce ical ca cinoma. In J Gynecol
Pa hol, 2008. 27(4): p. 568-74.
154. Pinhei o, C., e al., Monoca boxyla e anspo e 1 is up- egula ed in basal-
like b eas ca cinoma. His opa hology, 2010. 56(7): p. 860-7.
155. Pinhei o, C., e al., Exp ession o monoca boxyla e anspo e s 1, 2, and 4
in human umou s and hei associa ion wi h CD147 and CD44. J Biomed
Bio echnol, 2010. 2010: p. 427694.
156. Koukou akis, M.I., e al., Lung cance : a compa a i e s udy o me abolism
ela ed p o ein exp ession in cance cells and umo associa ed s oma.
Cance Biol The , 2007. 6(9): p. 1476-9.
157. Ri zhaup , A., e al., Iden i ica ion o a monoca boxyla e anspo e iso o m
ype 1 (MCT1) on he luminal memb ane o human and pig colon. Biochem
Soc T ans, 1998. 26(2): p. S120.
158. Lambe , D.W., e al., Molecula changes in he exp ession o human
colonic nu ien anspo e s du ing he ansi ion om no mali y o
malignancy. B J Cance , 2002. 86(8): p. 1262-9.
159. Chen, H., e al., Co-exp ession o CD147/EMMPRIN wi h monoca boxyla e
anspo e s and mul iple d ug esis ance p o eins is associa ed wi h
epi helial o a ian cance p og ession. Clin Exp Me as asis, 2010. 27(8): p.
557-69.
160. Pinhei o, C., e al., The p ognos ic alue o CD147/EMMPRIN is associa ed
wi h monoca boxyla e anspo e 1 co-exp ession in gas ic cance . Eu J
Cance , 2009. 45(13): p. 2418-24.
161. Tennan , D.A., R.V. Du an, and E. Go lieb, Ta ge ing me abolic
ans o ma ion o cance he apy. Na Re Cance , 2010. 10(4): p. 267-77.
162. Wahl, M.L., e al., Regula ion o in acellula pH in human melanoma:
po en ial he apeu ic implica ions. Mol Cance The , 2002. 1(8): p. 617-28.
163. Colen, C.B., e al., Me abolic emodeling o malignan gliomas o enhanced
sensi iza ion du ing adio he apy: an in i o s udy. Neu osu ge y, 2006.
59(6): p. 1313-23; discussion 1323-4.
164. Gallaghe , S.M., J.J. Cas o ino, and N.J. Philp, In e ac ion o
monoca boxyla e anspo e 4 wi h be a1-in eg in and i s ole in cell
mig a ion. Am J Physiol Cell Physiol, 2009. 296(3): p. C414-21.
165. Izumi, H., e al., Monoca boxyla e anspo e s 1 and 4 a e in ol ed in he
in asion ac i i y o human lung cance cells. Cance Sci, 2011. 102(5): p.
1007-13.
166. Colen, C.B., e al., Me abolic a ge ing o lac a e e lux by malignan glioma
inhibi s in asi eness and induces nec osis: an in i o s udy. Neoplasia,
2011. 13(7): p. 620-32.
167. O ens, M.J., e al., AR-C155858 is a po en inhibi o o monoca boxyla e
anspo e s MCT1 and MCT2 ha binds o an in acellula si e in ol ing
ansmemb ane helices 7-10. Biochem J, 2010. 425(3): p. 523-30.
168. Le Floch, R., e al., CD147 subuni o lac a e/H+ sympo e s MCT1 and
hypoxia-inducible MCT4 is c i ical o ene ge ics and g ow h o glycoly ic
umo s. P oc Na l Acad Sci U S A, 2011. 108(40): p. 16663-8.
169. Cen e , M.M., e al., In e na ional a ia ion in p os a e cance incidence and
mo ali y a es. Eu U ol, 2012. 61(6): p. 1079-92.
170. Heiden eich, A., e al., EAU guidelines on p os a e cance . Eu U ol, 2008.
53(1): p. 68-80.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
53
171. Hsing, A.W., L. Tsao, and S.S. De esa, In e na ional ends and pa e ns o
p os a e cance incidence and mo ali y. In J Cance , 2000. 85(1): p. 60-7.
172. Po osky, A.L., e al., Rise in p os a ic cance incidence associa ed wi h
inc eased use o ansu e h al esec ion. J Na l Cance Ins , 1990. 82(20):
p. 1624-8.
173. Po osky, A.L., e al., The ole o inc easing de ec ion in he ising incidence
o p os a e cance . JAMA, 1995. 273(7): p. 548-52.
174. Boyle, P., P. Maisonneu e, and P. Napalko , Geog aphical and empo al
pa e ns o incidence and mo ali y om p os a e cance . U ology, 1995.
46(3 Suppl A): p. 47-55.
175. Quinn, M. and P. Babb, Pa e ns and ends in p os a e cance incidence,
su i al, p e alence and mo ali y. Pa II: indi idual coun ies. BJU In ,
2002. 90(2): p. 174-84.
176. Quinn, M. and P. Babb, Pa e ns and ends in p os a e cance incidence,
su i al, p e alence and mo ali y. Pa I: in e na ional compa isons. BJU
In , 2002. 90(2): p. 162-73.
177. Wol , A.M., e al., Ame ican Cance Socie y guideline o he ea ly de ec ion
o p os a e cance : upda e 2010. CA Cance J Clin, 2010. 60(2): p. 70-98.
178. Heiden eich, A., e al., [EAU guidelines on p os a e cance . Pa I:
sc eening, diagnosis, and ea men o clinically localised disease]. Ac as
U ol Esp, 2011. 35(9): p. 501-14.
179. Jani, A.B. and S. Hellman, Ea ly p os a e cance : clinical decision-making.
Lance , 2003. 361(9362): p. 1045-53.
180. Eps ein, J.I., Upda e on he Gleason g ading sys em. Ann Pa hol, 2011.
31(5 Suppl): p. S20-6.
181. Eps ein, J.I., An upda e o he Gleason g ading sys em. J U ol, 2010.
183(2): p. 433-40.
182. Edge, S.B. and C.C. Comp on, The Ame ican Join Commi ee on Cance :
he 7 h edi ion o he AJCC cance s aging manual and he u u e o TNM.
Ann Su g Oncol, 2010. 17(6): p. 1471-4.
183. Hoedemaeke , R.F., A.N. Vis, and T.H. Van De Kwas , S aging p os a e
cance . Mic osc Res Tech, 2000. 51(5): p. 423-9.
184. Dambe , J.E. and G. Aus, P os a e cance . Lance , 2008. 371(9625): p.
1710-21.
185. F ankel, S., e al., Sc eening o p os a e cance . Lance , 2003. 361(9363):
p. 1122-8.
186. Higgins, L.H., e al., Hypoxia and he me abolic pheno ype o p os a e
cance cells. Biochim Biophys Ac a, 2009. 1787(12): p. 1433-43.
187. E e , P., e al., Exp ession o glucose anspo e 1 (Glu -1) in cell lines
and clinical specimens om human p os a e adenoca cinoma. An icance
Res, 2004. 24(5A): p. 3057-63.
188. S ewa , G.D., e al., Analysis o hypoxia-associa ed gene exp ession in
p os a e cance : lysyl oxidase and glucose anspo e -1 exp ession
co ela e wi h Gleason sco e. Oncol Rep, 2008. 20(6): p. 1561-7.
189. Vaz, C.V., e al., And ogen- esponsi e and non esponsi e p os a e cance
cells p esen a dis inc glycoly ic me abolism p o ile. In J Biochem Cell Biol,
2012. 44(11): p. 2077-84.
190. Nanni, C., e al., 11C/ 18F-choline PET o 11C/18F-ace a e PET in p os a e
cance : may a choice be ecommended? Eu J Nucl Med Mol Imaging,
2007. 34(10): p. 1704-5.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
60

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
61
2.2.1 Monoca boxyla e anspo e 4 (MCT4) and CD147 o e exp ession is
associa ed wi h poo p ognosis in P os a e Cance
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
62
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
63
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
64
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
65

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
66
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
67
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
68
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
69
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
76

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
77
3.2.1 Monoca boxyla e anspo e 2 (MCT2) as a pu a i e bioma ke in
p os a e cance .
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
78
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
79
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
80
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
81

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
82
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
83
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
84
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
85
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
92
gluconeogenic subs a e [8-13]. As MCT1, MCT2 is also ound in mi ochond ia
[12,13] and was also localized a pe oxisomes in non- umo li e ac ions [14].
The p esence o MCTs in mi ochond ia is jus i ied by he need o a py u a e ca ie
ha plays a cen al ole in ca bohyd a e and a me abolism. In con as , he
p esence o MCT1 and MCT2 in pe oxisomes was jus i ied as being in ol ed in a
lac a e-py u a e shu le sys em p esen in he memb ane o his o ganelle. This
shu le was sugges ed o be in ol ed in he oxida ion o NADH gene a ed by β-
oxida ion, being c ucial o he main enance o pe oxisomal iabili y and
consequen β-oxida ion a es [14]. This was he only s udy ega ding his ma e
and i was no done in he cance con ex , as so, li le is known abou lac a e
shu les as well as he in ol emen o pe oxisomal al e a ions in cance .
In his wo k we aimed o un a eling MCT2 in acellula localiza ion and exp ession
ac oss p os a e malignan ans o ma ion using di e en models o disease
p og ession in o de o in e abou he impo ance o his iso o m in p os a e
cance disease. Also, he o he MCT iso o ms whe e assessed in o de o
cha ac e ize in mo e de ail hei in acellula dis ibu ion.
Ma e ial and me hods
Cell cul u e
In his s udy we ha e used di e en p os a e cell lines, PNT1A (non-malignan ),
22R 1 (localized umo ), LNCaP (lymph node me as asis) and PC3 (bone
me as asis). Cells we e seeded in RPMI-1640 (Gibco, In i ogen, USA)
supplemen ed wi h 10% o e al bo ine se um (FBS) (PAA Labo a o ies GmbH,
Cölbe, Ge many), 1% o an ibio ic (penicillin/s ep omycin) (PAA Labo a o ies
GmbH, Cölbe, Ge many) and incuba ed a 37⁰C in an a mosphe e con aining 5%
CO2.
Immuno luo escence and mic oscopy echniques
Immuno luo escence was pe o med in o de o iden i y he in acellula
localiza ion o MCT1, MCT2 (sc-14926, San a C uz Bio echnology, San a C uz,
CA), MCT4 and i s chape ones CD147 and gp70. Fluo opho es TRITC (Jackson

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
93
ImmunoResea ch) and Alexa 488 (In i ogen, Li e Technologies, G and Island,
NY, USA) we e used as seconda y an ibodies.
Immuno luo escence was pe o med in cells seeded on glass co e slips ha we e
ixed a e 24h wi h 4 % pa a o maldehyde in PBS, pH 7.4 o 20 min. A e wa ds
cells we e pe meabilized wi h 0.2 % T i on X-100 o 10 min, blocked wi h 1 %
BSA solu ion o 10 min and incuba ed wi h p ima y (MCT2, ca alase, PEX19 and
Gp70) and seconda y an ibodies [TRITC (Jackson ImmunoResea ch) and Alexa
488 (In i ogen, Li e Technologies, G and Island, NY, USA)] o 1 h each.
Be ween each s ep, cells we e ex ensi ely insed 3 imes wi h PBS, pH 7.4. Las ly,
cells we e s ained wi h and moun ed in slides using Mowiol 4-88 con aining n-
p opylgalla e. Images we e ob ained using a Zeiss LSM 510 Me a Con ocal se up
(Ca l Zeiss, Obe kochen, Ge many) equipped wi h a plan-Apoch oma 100×/1.4 oil
objec i e.
Wes e n Blo
Cells we e lysed wi h speci ic lysis bu e (25 mM T is-HCl, pH 8.0, 50 mM sodium
chlo ide, 0.5% sodium deoxychola e, 0.5% T i on X-100 and a p o ease-inhibi o
mix). To imp o e p o ein ex ac ion, samples we e passed 20 imes h ough a 26-
gauge sy inge needle and incuba ed on a o a y mixe a o 30 min a 4⁰C. A e
clea ed by cen i uga ion (13300 pm, 15 min) p o ein concen a ions we e
de e mined by he B ad o d assay (BioRad, He cules, CA, USA). Blo s we e
incuba ed wi h speci ic p ima y an ibodies, MCT2, gp70, PEX14, Ca alase,
ACOX1, ACOX3 and PEX19. The an ibodies we e de ec ed by a ho se adish
pe oxidase-linked seconda y an ibody using an enhanced chemiluminescence
sys em (GE Heal hca e, Waukesha, WI, USA).
Immunop ecipi a ion
22R 1 cells we e ans ec ed wi h Pex19-YFP using Tu bo ec in i o ans ec ion
ki (Fe men as, USA), acco ding o he manu ac u e ’s ins uc ions. Fo
immunop ecipi a ion o Pex19-YFP we used GFP ap_M (Ch omo ek).
T ans ec ion wi h a plasmid con aining GFP was used as nega i e con ol. A e
48h o ans ec ion cell pelle s we e incuba ed lysis bu e (10mM T is-HCl, pH 7.5,
150mMNaCl, 0.5mM EDTA, 0.5%NP-40 and a p o ease-inhibi o mix). The lysa e
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
94
was clea ed by cen i uga ion (13300 pm, 15 min) and dilu ed wi h dilu ion bu e
(10mM T is-HCl, pH 7.5, 150mM NaCl, 0.5mM EDTA and a p o ease-inhibi o
mix). P o ein concen a ions we e de e mined by he B ad o d assay (BioRad,
He cules, CA, USA). Ice-cold dilu ion bu e was used o equilib a e beads and cell
lysa es we e incuba ed o 2 h a 4°C on a o a y mixe . Beads we e washed 3
imes wi h dilu ion bu e and esuspended in 3x SDS-sample bu e and boiled o
10 min o elu e bound p o eins. Immunop ecipi a ed samples we e sepa a ed by
unning in a 12.5% SDS-polyac ylamide gel.
Resul s
MCT2 was de ec ed in he pe oxisomes o p os a e cance cells a di e en
le els wi hin disease p og ession
The in acellula localiza ion o MCT2 was accessed in di e en models o p os a e
cance disease p og ession. As McClelland e al ha e shown a pe oxisomal
localiza ion o MCT2 in non- umo li e ac ions, we i s ly es ed whe he his
p o ein would also be p esen in his o ganelle in p os a e cance cells. To ha
end, we ha e pe o med immunolocaliza ion o MCT2 oge he wi h he
pe oxisomal ma ke ca alase in di e en p os a e cell lines: PNT1A (non-
malignan ), 22R 1 (localized umo ), LNCaP (lymph node me as asis) and PC3
(bone me as asis). Ou esul s demons a e ha , while no co-localiza ion was
obse ed be ween MCT2 and he pe oxisomal ma ke in PNT1A, his p o ein is
localized a pe oxisomes in all he malignan cell lines (Fig 1). We ha e, hough,
obse ed ha he localiza ion le el a ied ac oss he di e en models. In 22R 1
cells, MCT2 was mainly ound in he pe oxisomes wi h a mino po ion sp ead
h oughou he cy oplasm as small agg ega es (Fig1 d- ). Howe e , he a io o
pe oxisomal MCT2/cy oplasm MCT2 dec eased wi h disease p og ession,
culmina ing wi h almos no MCT2 in he pe oxisomes in PC3 cells (Fig1 j-l).
Su p isingly, he amoun o MCT2 a pe oxisomes appea s o co ela e wi h a
change on he o ganelle’s mo phology. In ac , in cells whe e no MCT2 was
p esen in pe oxisomes (PNT1A), his o ganelle exhibi s a egula pheno ype (Fig
1A: a-c). Cu iously, in 22R 1 cells (whe e MCT2 was mainly obse ed in
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
95
pe oxisomes) his o ganelle appea s somewha in clus e s (Fig. 1A: d- ) LNCaP
cells exhibi mo e dis ibu ed ounde pe oxisomes wi h only a ew clus e s
(Fig.1A: g-i). In PC3, he highly me as a ic model, pe oxisomes appea simila o
he ones o he non-malignan cells PNT1A (Fig 1A: j-l). S ikingly, he exp ession
le el o MCT2 inc eases om non- umo (PNT1A) o localized malignan cells
(22R 1), co ela ing o i s change in localiza ion om cy oplasmic o pe oxisomal
(Fig 1B). This inc ease in exp ession was also obse ed o Pex14 (a pe oxisomal
memb ane p o ein) (Fig 1C), sugges ing an inc ease in pe oxisomal memb ane
su ace/numbe ha accompanies he malignan ans o ma ion.
MCT2 a els o he pe oxisomal memb anes ough PEX19
The quick mo emen o monoca boxyla es ac oss he memb anes is impe a i e o
cellula me abolism. These p o eins a e hough o equi e chape ones such as
CD147 in he case o MCT1 and MCT4, o gp70 in he case o MCT2, o
app op ia e exp ession and ac i i y in he plasma memb ane [15]. Since MCT2
was he only iso o m ound o localize in pe oxisomes in p os a e cance cells, we
aimed a un a eling i s a ge ing mechanism o his o ganelle. A p e ious s udy
was unable o ind gp70 exp ession in human p os a e samples ha exhibi ed
MCT2 exp ession [5]. Howe e , ou s udies wi h con ocal mic oscopy allowed us
o obse e some, al hough sca ce, gp70 dis ibu ed in he cy oplasm wi hou any
co-localiza ion wi h pe oxisomal ma ke s (Fig 2 a-l). Hence, he p o ein ha
beha es as chape one o MCT2 anspo o pe oxisomes in p os a e cells is s ill
unknown.
As Pex19 is he main p o ein esponsible o he anspo o pe oxisomal
memb ane p o eins o his o ganelle, we es ed whe he his p o ein could ac as a
chape one o MCT2 in hese cells. Being 22RV1 he cell line whe e MCT2 was
mainly p esen a pe oxisomes, i was he chosen model o s udy he possible
in e ac ion be ween MCT2 and PEX19. Immunop ecipi a ion expe imen s ha e
shown, indeed, an in e ac ion be ween MCT2 and PEX19 (Fig 3). These esul s
sugges a highjack o he pe oxisomal anspo mechanism by he p os a e cance
cells.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
96
The p esence o MCT2 a pe oxisomes seems o be ela ed wi h an inc ease
in he a es o pe oxisomal β-oxida ion
McClelland e al obse ed a dec ease in β-oxida ion upon MCTs inhibi ion,
sugges ing ha he p esence o MCT2 a pe oxisomes o non-malignan li e cells
would be essen ial o he main enance o pe oxisomal iabili y and consequen ly
β-oxida ion a es. Hence, we hypo hesized ha he inc ease o MCT2 exp ession
om non-malignan p os a e cells (PNT1A) o localized p os a e umo cells
(22RV1) could be ela ed wi h an inc ease in pe oxisomal β-oxida ion. In ac , we
obse ed an inc ease in he exp ession le els o ACOX1 and ACOX-3, cen al
p o eins in he β-oxida ion pa hway (Fig 4). These esul s in e es ingly sugges
ha , indeed, he inc ease in MCT2 exp ession le els as well as i s p esence a
pe oxisomes, a e ela ed o an inc ease in β-oxida ion le els which may be c ucial
o malignan ans o ma ion.
The dis ibu ion o o he MCTs iso o ms and CD147 a in acellula le el
sugges s an addi ional ole o hese p o eins in p os a e cance
MCT1, MCT4 and CD147 exp essions we e also e alua ed in his s udy. MCT1
showed a s ong nuclea exp ession in PNT1a and 22RV1, dec easing o LNCaP
and PC3, whe e his anspo e was mainly ound in he cy oplasm and plasma
memb ane (Fig.5). MCT4 howe e was shown o be p esen in he cy oplasm o
he less umo igenic cell lines 22RV1 and LNCaP in con as o he highly
me as a ic PC3 whe e i was clea ly p esen a he plasma memb ane (Fig.6).
CD147 was p esen in he plasma memb ane, cy oplasm and nuclea en elope
(Fig.7).
In e es ingly, some co-localiza ion be ween MCTs 1 and 4 and pe oxisomes, was
also e i ied, howe e i was less e iden han o MCT2.
Discussion
I is now widely accep ed ha he anspo o lac a e and py u a e is media ed by
a amily o H+/monoca boxyla e anspo e s (MCTs) known o hei speci ici y o
anspo sho chain monoca boxyla es. They o m an in eg al pa o p oposed
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
97
shu les ha anspo lac a e be ween cells (cell–cell lac a e shu le) and wi hin
cells (in acellula lac a e shu le).
A p e ious s udy o MCTs exp ession in p os a e cance d ew a en ion o MCT2
ha was shown o be clea ly exp essed in p os a e malignan glands bu a he
cy oplasm, sugges ing he in ol emen o his anspo e in an o ganelle
memb ane [6], howe e he e we e no s udies desc ibing he exis ence o MCT2 in
he o ganelles o p os a e cance cells.
I is known, ha once in he mi ochond ial ma ix, lac a e and py u a e unde go
u he b eakdown making i di icul o in e hei espec i e oles in he shu ling o
educing equi alen s o he elec on anspo chain. Pe oxisomes, on he o he
hand, lack he enzymes o ca abolize monoca boxyla es and al hough hey a e
known o con ain LDH [16], hey a e no known o con ain any o he glycoly ic o
any ica boxylic acid cycle enzymes. One o he many unc ions o li e
pe oxisomes is he β-oxida ion o long b anched-chain a y acids and o he
main enance o hese eac ions inside he pe oxisome, a edox shu le sys em
exis ac oss he pe oxisomal memb ane o eoxidize NADH. I is essen ial o he
con inuous unc ioning o pe oxisomes ha p ope in a-o ganelle educ ion–
oxida ion ( edox) balance is main ained ha ensu es he eoxida ion o NADH
p oduced by β-oxida ion and he con inuous b eakdown o a y acids. Redox
balance in many o ganelles is main ained in pa by subs a e shu les. This would
en ail a shu le sys em in pe oxisomes ha nei he gene a es p oduc s no
consumes any subs a es.
McClelland e al p oposed ha a edox shu le sys em ha consis s o a subs a e
cycle be ween lac a e and py u a e, as so, o play hei ole in pe oxisomal edox
balance, py u a e and lac a e mus be anspo ed ac oss he pe oxisomal
memb ane [14].
In he p esen s udy we desc ibe o he i s ime ha MCT2 is p esen in human
p os a e pe oxisomes and a possible explana ion o how hese MCT2 ends up in
he pe oxisomal memb ane was gi en by he e iden in e ac ion o MCT2 wi h
PEX19 which migh ac as chape one. The absence o glycolysis in his o ganelle
s ongly sugges s ha his shu le se es o main ain edox balance and no
glycolysis o some o he me abolic unc ion. Consequen ly, we poin ou he
impo ance o pe oxisomes in p os a e cance cells ha as i was obse ed a clea

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
98
change hei mo phology ac oss p os a e malignan ans o ma ion, which p o ides
u he e idence o he dynamic na u e o he pe oxisomes ac oss disease
p og ession. Impo an ly, he equency o pe oxisomal clus e s and he co-
localiza ion wi h MCT2 ha was mainly obse ed in he ansi ion om he benign
model (PNT1a) o he malignan model (22RV1), poin o he in ol emen o hese
al e a ions in umou ini ia ion. Finally, he possibili y o ha ing MCT1 and MCT4 in
he pe oxisomal memb ane, howe e less e iden han o MCT2, co obo a es he
hypo hesis o al e na i e oles o hese anspo e s in me abolic pa hways
di e en om glycolysis in he p esen cells. Howe e , u he s udies a e needed
o unde s and he ole o hese MCT iso o ms in p os a e pe oxisomes.
Re e ences
1. Compe a , E., J. Va ino , and J.R. S igley, [Benign mimicke s o he p os a e cance .
Diagnos ic challenges]. Ann Pa hol, 2013. 33(4): p. 237-46.
2. Schmi z, W., R. Finge hu , and E. Conzelmann, Pu i ica ion and p ope ies o an alpha-
me hylacyl-CoA acemase om a li e . Eu J Biochem, 1994. 222(2): p. 313-23.
3. Lloyd, M.D., e al., Alpha-me hylacyl-CoA acemase--an 'obscu e' me abolic enzyme akes
cen e s age. FEBS J, 2008. 275(6): p. 1089-102.
4. Hales ap, A.P., The SLC16 gene amily - s uc u e, ole and egula ion in heal h and
disease. Mol Aspec s Med, 2013. 34(2-3): p. 337-49.
5. Pe ega-Gomes, N., e al., Monoca boxyla e anspo e 4 (MCT4) and CD147
o e exp ession is associa ed wi h poo p ognosis in p os a e cance . BMC Cance , 2011.
11: p. 312.
6. Pe ega-Gomes, N., e al., Monoca boxyla e anspo e 2 (MCT2) as pu a i e bioma ke in
p os a e cance . P os a e, 2013. 73(7): p. 763-9.
7. Lin, R.Y., e al., Human monoca boxyla e anspo e 2 (MCT2) is a high a ini y py u a e
anspo e . J Biol Chem, 1998. 273(44): p. 28959-65.
8. Pie e, K., e al., Cell-speci ic localiza ion o monoca boxyla e anspo e s, MCT1 and
MCT2, in he adul mouse b ain e ealed by double immunohis ochemical labeling and
con ocal mic oscopy. Neu oscience, 2000. 100(3): p. 617-27.
9. Pie e, K., P.J. Magis e i, and L. Pelle in, MCT2 is a majo neu onal monoca boxyla e
anspo e in he adul mouse b ain. J Ce eb Blood Flow Me ab, 2002. 22(5): p. 586-95.
10. Debe na di, R., e al., Cell-speci ic exp ession pa e n o monoca boxyla e anspo e s in
as ocy es and neu ons obse ed in di e en mouse b ain co ical cell cul u es. J Neu osci
Res, 2003. 73(2): p. 141-55.
11. Pelle in, L., e al., Cellula and subcellula dis ibu ion o monoca boxyla e anspo e s in
cul u ed b ain cells and in he adul b ain. J Neu osci Res, 2005. 79(1-2): p. 55-64.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
99
12. Yoshida, Y., e al., Negligible di ec lac a e oxida ion in subsa colemmal and
in e myo ib illa mi ochond ia ob ained om ed and whi e a skele al muscle. J Physiol,
2007. 582(P 3): p. 1317-35.
13. Ben on, C.R., e al., Monoca boxyla e anspo e s in subsa colemmal and in e myo ib illa
mi ochond ia. Biochem Biophys Res Commun, 2004. 323(1): p. 249-53.
14. McClelland, G.B., e al., Pe oxisomal memb ane monoca boxyla e anspo e s: e idence
o a edox shu le sys em? Biochem Biophys Res Commun, 2003. 304(1): p. 130-5.
15. Wilson, M.C., e al., Basigin (CD147) is he a ge o o ganome cu ial inhibi ion o
monoca boxyla e anspo e iso o ms 1 and 4: he ancilla y p o ein o he insensi i e
MCT2 is EMBIGIN (gp70). J Biol Chem, 2005. 280(29): p. 27213-21.
16. Baumga , E., e al., L-lac a e dehyd ogenase A4- and A3B iso o ms a e bona ide
pe oxisomal enzymes in a li e . E idence o in ol emen in in ape oxisomal NADH
eoxida ion. J Biol Chem, 1996. 271(7): p. 3846-55.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
100
Figu es
Figu e 1 A) Immunohis ochemical images o di e en human p os a e cell lines PNT1a (Figu e 1a-
c), 22RV1(Figu e 1d- ), LNCaP (Figu e 1g-i) and PC3 (Figu e 1j-l). Supe posi ion o signals om
p obes o MCT2 (g een), and Ca alase ( ed) shows clea colocaliza ion (yellow in he pe oxisomes
o p os a e cance cells).
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
101
PNT1a 22RV1 LNCaP PC3
MCT2
βTubulin
Figu e 1 B) Wes e n blo analysis showing he le els o MCT2 in he di e en p os a e cell line
models.
PNT1a 22RV1 LNCaP PC3
PEX14
Tubulin
Figu e 1 C) Wes e n blo analysis, showing he exp ession le els o he pe oxisomal p o ein PEX-
14 in he di e en in i o models o p os a e cance p og ession (PNT1a, 22RV1, LNCaP and
PC3).
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
108

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
109
4.1 CHAPTER OVERVIEW
We i s ly desc ibed o e exp ession o MCT2 and MCT4 in PCa issues when
compa ed o he no mal coun e pa s, howe e , he ole o MCTs in PCa
me abolism is s ill la gely unknown. The p esence o MCT4 in he cy oplasm o
p os a e cance cells ins ead o plasma memb ane oge he wi h he exp ession
o MCT1 in bo h non-malignan and malignan glands, sugges ed ha p os a e
cells may no i s ly ely on glycoly ic me abolism as he majo i y o umou s.
This e i ica ion u ned his wo k e en mo e challenging in an a emp o
con ex ualize he ole o di e en MCTs iso o ms ac oss p os a e malignan
ans o ma ion and p og ession.
As s a ed be o e, i emains unclea wha is he p ima y ene ge ic pa hway in
PCa and he e o e which me abolic pa hway ep esen s he mos app op ia e
a ge o me abolic inhibi ion in PCa. The e a e s udies epo ing he p esence
o hypoxia in PCa, poin ing o he p esence o a glycoly ic pheno ype, howe e
o he s udies epo ha PCa is cha ac e ized by low a es o glycolysis and a
low FDG ac i i y on PET imaging. This ac aises he hypo hesis ha i glucose
consump ion is no ele a ed in PCa, al e na i e me abolic pa hways mus
p o ide he ene gy needed o cance cell p oli e a ion and g ow h. Some
e idence suppo a c ucial ole o a y acid- ela ed me abolism in he
pa hogenesis and p og ession o p os a e malignancy. Howe e , he epo s a e
sca ce wi h low numbe o clinical samples and wi h no in o ma ion ega ding
he clinico-pa hological signi icance o hese al e a ions; as so, PCa me abolism
is s ill la gely unknown.
This chap e includes esul s al eady submi ed o publica ion, showing he
exp ession pa e n o se e al me abolic- ela ed p o eins in ol ed in glycoly ic
and a y acid oxida ion pa hways om benign p os a e o me as a ic PCa,
in es iga ing he p ognos ic impac o hei exp ession. Also, using di e en in
i o models o disease p og ession we es ed how he inhibi ion o hese
pa hways a ec he di e en models o p os a e cance cells in o de o
es ablish a a ionale o me abolic pheno ypes ac oss p os a e malignan
ans o ma ion and p og ession.
O e all, he esul s p esen ed he e indica e a swi ch om less agg essi e umo
o glycoly ic me abolism in he highly agg essi e and me as a ic p os a e umo
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
110
and unde sco es he plas ici y o bioene ge ic pa hways in p os a e cance cells
which migh ha e c ucial implica ions a p ognos ic and he apeu ic le el.
4.2 PUBLISHED RESULTS
The esul s p esen ed in his chap e we e:
(i) Submi ed o publica ion as an o iginal a icle in an in e na ional pee
e iewed jou nal
Pé ega-Gomes N, Vizcaíno JR, Sousa S, Coelho R, A ig J, Ju meis e S,
Oli ei a E, Pe ei a L, Pinhei o C, Je ónimo C, Hen ique RM, Lobo da Cunha A,
Lopes C, Maximo V and Bal aza F “Me abolic he e ogenei y in p os a e cance
is linked o disease p og ession and agg essi eness”. 2013.
(ii) In i ed o publica ion as an o iginal a icle in an in e na ional pee
e iewed jou nal
Pé ega-Gomes N. and Bal aza F. “MCTs as a ge s o p os a e cance
he apy?” in i ed wo k o be published in Ad ances in P os a e Cance
Resea ch and T ea men jou nal. 2014.
(iii) P esen ed as o al communica ion in he ollowing in e na ional
scien i ic mee ing
Pé ega-Gomes N, Vizcaíno JR, Lopes C and Bal aza F. “T acing he
me abolic p o ile o p os a e cance de elopmen ” wo k p esen ed a 23 d
Eu opean Cong ess o Pa hology a Helsinki, Finland. 2011.
Pé ega-Gomes N., Vizcaíno JR, Lopes C and Bal aza F. “Exploi a ion o
me abolic al e a ions as impo an e p ognos ic, diagnos ic and he apeu ic ools
in p os a e cance ”. Wo k p esen ed a 20 h Mee ing o he EAU Sec ion o
U ological Resea ch (ESUR). 25-27 Oc obe 2012, S asbou g, F ance. 2012.
(i ) P esen ed as o al communica ion in he ollowing na ional scien i ic
mee ing:
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
111
Pé ega-Gomes N, Lou enço T, Vizcaíno JR, Lopes C and Bal aza F. “S udy
o Me abolic p o ile o localized and me as a ic umou o he p os a e.
Monoca boxyla e anspo e s as he apeu ic a ge s” wo k p esen ed a XVI
Wo kshop on Oncological U ology, Ca oei o, Po ugal. 2011.
Pé ega-Gomes N, Lou enço T, Vizcaíno JR, Lopes C and Bal aza F. e al. “A
me abolic swi ch could be in ol ed in p os a e cance agg essi eness.”Wo k
p esen ed a he 12º Cong ess o he Po uguese Socie y o Oncology, Alga e,
Po ugal. 2011.
( ) P esen ed as pos e in he ollowing in e na ional scien i ic mee ing:
Pé ega-Gomes N, Lou enço T, Mi anda-Gonçal es V, Vízcaíno JR, Oli ei a E,
Je ónimo C, Lopes C, Lobo da Cunha A. and Bal aza F. “Eme ging oles o
Monoca boxyla e T anspo e s in p os a e cance me abolism”. a 2nd
Symposium o he In e na ional Socie y o P o on Dynamics in Cance in Nice,
F ance. 2011.
Mi anda-Gonçal es V, Pé ega-Gomes N, Lou enço T, Pinhei o C, Je ónimo C,
Vizcaíno JR, Lopes C, and Bal aza F. “P os a e Cance : exploi a ion o
monoca boxyla e anspo e s as po en ial he apeu ic a ge s”. a he 39 h
Mee ing o In e na ional Socie y o Oncology and Bioma ke s in Flo ence, I aly.
2011.
Pé ega-Gomes N., Vizcaíno JR, Lou enço T, Lopes C. and Bal aza F
“Exploi ing me abolic al e a ions in p os a e cance diagnosis and p ognosis” a
XXI Po o Cance Mee ing, Po o. 2012.
Pé ega-Gomes N, Vizcaíno JR, Lou enço T, Lopes C. and Bal aza F “T acing
he me abolic p o ile o p os a e cance p og ession. Roles o monoca boxyla e
anspo e s (MCTs) in p os a e cance me abolism” a EACR Annual Cong ess,
Ba celona. 2012.
Pé ega-Gomes N, Vizcaíno JR, Lou enço T, Lopes C. and Bal aza F. “Clinical
impac o he me abolic pheno ype o p os a e cance : Role o monoca boxyla e
anspo es (MCTs).” a São Paulo Ad anced School o Compa a i e Oncology.
Sep embe 30 h o Oc obe 6 h. Águas de São Ped o-São Paulo, B asil. 2012.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
112
Pé ega-Gomes N, Vizcaíno JR, Lou enço T, Lopes C. and Bal aza F.
“Me abolic pheno ypes associa ed wi h dis inc and ogen- esponsi e condi ions
can be a aluable ool o diagnos ic and he apeu ic op ions in p os a e
cance .” a A one day symposium wi h Ca los Caldas sponso ed by EACR. 29TH
Oc obe , Po o, Po ugal. 2012.
( i) We e ecognized wi h he he ollowing p izes/awa ds:
Pé ega-Gomes N, Vizcaíno JR, Lopes C and Bal aza F “T acing he
me abolic p o ile o p os a e cance de elopmen ”. Bu sa y Awa d gi en by he
Eu opean Socie y o Pa hology (ESP) o a end 23º Cong ess o he Eu opean
Socie y o Pa hology mee ing in Helsinki, Finland.
Pé ega-Gomes N, Lou enço T., Vizcaíno JR, Lopes C and Bal aza F. “S udy
o Me abolic p o ile o localized and me as a ic umou o he p os a e.
Monoca boxyla e anspo e s as he apeu ic a ge s” 1s P ize (Janssen Awa d)
and Hono able Men ion gi en by o bes pos e and scien i ic
communica ion in Na ional Cong ess o U ology.
Pé ega-Gomes N, Lou enço T., Vizcaíno JR, Lopes C and Bal aza F. 2011.
“A me abolic swi ch could be in ol ed in p os a e cance agg essi eness. 1s
P ize o bes pos e and scien i ic communica ion in 12º Na ional Cong ess
o Oncology.
Pé ega-Gomes N, Vizcaíno JR, Lou enço T, Lopes C. and Bal aza F. 2012.
“Clinical impac o he me abolic pheno ype o p os a e cance : Role o
monoca boxyla e anspo es (MCTs).” Bu sa y awa d gi en by FAPESP -
São Paulo Resea ch Founda ion o a end ESPCA-School o Compa a i e
Oncology a Águas de São Ped o-São Paulo, B asil, 2012.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
113
4.3.1 Me abolic he e ogenei y in p os a e cance is linked o disease
p og ession and agg essi eness

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
114
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
115
Me abolic he e ogenei y in p os a e cance is linked o disease
p og ession and agg essi eness
Running Ti le: Me abolic he e ogenei y in PCa p og ession
Lis o au ho s
Nelma Pé ega-Gomes1,2, José R. Vizcaíno3, Susana Sousa1,2, Rica do
Coelho4,5, Jan A ig6, Sa ah Ju meis e 7, Elsa Oli ei a8, Luísa Pe ei a4, 9, Céline
Pinhei o1,2, Ca men Je ónimo10,11,12, Rui M. Hen ique11,12,13, Alexand e Lobo da
Cunha8, Ca los Lopes3,12, Valdema Maximo4,9and Fá ima Bal aza 1,2*
1Li e and Heal h Sciences Resea ch Ins i u e (ICVS), School o Heal h
Sciences, Uni e si y o Minho, B aga, Po ugal
2ICVS/3B’s - PT Go e nmen Associa e Labo a o y, B aga/Guima ães,
Po ugal;
3Depa men o Pa hology, Cen o Hospi ala do Po o, Po ugal;
4Ins i u e o Molecula Pa hology and Immunology o he Uni e si y o Po o
(IPATIMUP), 4200-465 Po o, Po ugal.
5Ins i u e o Biomedical Sciences o Abel Salaza , Uni e si y o Po o, 4050-313
Po o, Po ugal.
6MRC Labo a o y o Molecula Biology F ancis C ick A enue Camb idge
Biomedical Campus Camb idge UK.
7U o-oncology Resea ch G oup, Cance Resea ch UK Camb idge Ins i u e,
Uni e si y o Camb idge, Camb idge, UK.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
116
8Labo a o y o Cell Biology, Ins i u e o Biomedical Sciences Abel Salaza
(ICBAS), Uni e si y o Po o
9Depa men o Pa hology and Oncology, Medical Facul y o he Uni e si y o
Po o, 4200-319 Po o, Po ugal
10Cance Epigene ics G oup – Resea ch Cen e , Po uguese Oncology Ins i u e-
Po o, Po o, Po ugal;
11Depa men o Gene ics, Po uguese Oncology Ins i u e,Po o, Po ugal
12Depa men o Pa hology and Molecula Immunology, Ins i u e o Biomedical
Sciences Abel Salaza (ICBAS), Uni e si y o Po o, Po o, Po ugal
13Depa men o Pa hology, Po uguese Oncology Ins i u e-Po o, Po o,
Po ugal
*Co espondence o: Fá ima Bal aza , PhD, School o Heal h Sciences,
Uni e si y o Minho, Campus de Gual a , 4710-057 B aga, Po ugal.
email:[email p o ec ed]. Tel: +351 253 60 48 28. Fax: +351 253 60 48
20
Con lic o in e es s a emen
The au ho s decla e no con lic s o in e es .
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
117
Abs ac
Me abolic adap a ion is now conside ed a new hallma k o cance , in which
cance cells exhibi high a es o glucose consump ion wi h consequen lac a e
p oduc ion. Howe e , he dominan ene ge ic pa hway as well as he clinical
impac o al e ed cellula me abolism in p os a e cance is s ill la gely unknown.
In an a emp o unde s and he me abolic al e a ions du ing p os a e cance
p og ession and how hese al e a ions could ep esen sui able ools o
p os a e cance a diagnos ic, p ognos ic and he apeu ic le el, we s udied he
exp ession o se e al key me abolic- ela ed p o eins in 480 human p os a e
samples and using in i o models we assessed me abolic changes associa ed
wi h malignan ans o ma ion/p og ession and how hei manipula ion a ec s
di e en models o p os a e cance cells. Also we p o ided an insigh in o he
cell mi ochond ial ea u es and used publicly a ailable genome-wide exp ession
p o iling da ase s o assess he exp ession o he genes ha codi y me abolic-
ela ed p o eins du ing p os a e cance p og ession.
This s udy p o ides e idence o inc eased glycoly ic pheno ype mainly in he
ad anced s ages o p os a e cance , and i s co ela ion wi h poo p ognosis
whe eas he localized umou showed mo e consis en ly up egula ion o
p o eins in ol ed in pe oxisomal b anched-chain a y acid oxida ion wi hou any
associa ion wi h clinic-pa hological da a. Impo an ly, expe imen s using in i o
models showed ha cell lines de i ed om dis an me as asis a e mo e
glycoly ic, sensi i e o glycoly ic inhibi o s and wi h lowe ene gy e iciency a
he mi ochond ial le el.
This is he mos comp ehensi e s udy epo ing he me abolic di e ences
ac oss p os a e malignan ans o ma ion and co ela ing he me abolic
he e ogenei y o p os a e cance cells wi h un a o able p ognosis, showing ha
me abolic changes ha e a s ong po en ial o be explo ed as diagnos ic,
p ognos ic and he apeu ic ools in p os a e cance .
Keywo ds: p os a e cance , cance me abolism, monoca boxyla e anspo e s,
glycoly ic me abolism, a y acid oxida ion, me abolic swi ch.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
124
he e was a dec ease in he su i al o pa ien s wi h umou s exp essing CAIX,
(da a no shown).
Di e en in i o models o PCa p og ession exhibi di e en p o ein
exp ession and glycoly ic me abolism p o iles
Since he main di e ences obse ed ac oss malignan p og ession in human
samples we e ela ed o p o eins in ol ed in he glycoly ic me abolism, in Figu e
3 we show he exp ession p o ile o hese p o eins in di e en in i o models o
disease p og ession. In e es ingly, MCT4 and HIF-1alpha we e only p o eins
de ec ed in DU145 and PC3 cell lines. Also, GLUT-1, LDHV and CAIX showed
e iden highe le els in PC3 cell line. In e es ingly, he ICC esul s o he
di e en cell line models show ha MCT4 and GLUT-1 only appea ed e iden ly
exp essed a he plasma memb ane in he highly me as a ic models, such as
PC3, in con as o he low umo igenic cell line LNCaP (Figu e 3B).
Finally, a clea dis inc me abolic beha iou be ween he low umo igenic 22RV1
and LNCaP and he high umo igenic PC3 and DU145 models was obse ed.
PC3 and DU145 exhibi ed highe le els o glucose consump ion (Figu e 3C)
and lac a e p oduc ion (Figu e 3D) when compa ed o 22RV1 and LNCaP cells.
P os a e cance cells exhibi ed di e en sensi i i ies o inhibi ion o
glycolysis and a y acid oxida ion
Based in he idea ha di e en models o disease p og ession exhibi ed a
di e en me abolic beha iou , we aimed o s udy he e ec o glycolysis and
a y acid oxida ion inhibi ion in he di e en models.
Oxamic acid (OA), an inhibi o o lac ic dehyd ogenase (LDH), was used o in e
how he glycoly ic me abolism in he di e en models is a ec ed a e inhibi ion
o lac ic acid p oduc ion. Figu e 4 shows he glucose consump ion and lac a e
p oduc ion o p os a e cell lines a e he ea men wi h OA. I is possible o
obse e ha bo h pa ame e s showed a signi ican dec ease in 22RV1, PC3
and DU145 cell lines. In con as , LNCaP cell line me abolism was less a ec ed
by OA ea men .

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
125
The pheno hiazine d ug, hio idazine (TZ), desc ibed as a selec i e inhibi o o
pe oxisomal β-oxida ion, was also used in ou cell line models. As obse ed in
Figu e 5A, he IC50 alues show ha 22RV1 and LNCaP cell lines a e mo e
sensi i e o TZ e ec , especially a 72 h ea men . Acco dingly, when we
supplemen ed he cul u e media wi h phy anic acid (PA), a long b anched chain
a y acid, o s imula e a y acid oxida ion, a dec ease in PC3 and DU145 cell
iabili y was obse ed, bu no in 22RV1 and LNCaP ha main ain hei iabili y
wi h inc easing concen a ions o PA, e en a e 48 hou s o exposu e (Figu e
5B).
Ul as uc u al di e ences a e e iden among he di e en p os a e cance
cell models
So a , we ha e obse ed ha di e ences a he exp ession le els o p o eins
in ol ed in glycoly ic and a y acid me abolism as well as in cells me abolic
beha io a e e iden ac oss malignan ans o ma ion. As so, we also aimed o
e i y i such di e ences migh be also e lec ed a he ul as uc u al le el o he
cells. Figu e 6 shows elec on mic og aphs o LNCaP (Figu e 6A), PC3 (Figu e
6B) and wo di e en human samples o p os a e cance (Figu e 6C and 6D). I
was possible o obse e ha ei he in LNCaP cells o he human samples
(Figu e 6A, 6C and 6D, espec i ely), cells a e packed wi h lipid bodies. Also, in
wha conce ns mi ochond ia mo phology, hese images clea ly show di e ences
in e ms o subcellula ea u es o localized p os a e umou s and he low
umo igenic model LNCaP cell line in compa ison wi h he cells de i ed om
highly me as a ic umou s (PC3).
Analysis o he mi ochond ial genome e lec s a dec ease in he e iciency
o PC3 cell lines h ough inc eased exp ession o UCP2 p o ein
A comple e m DNA sequencing o he cell lines LNCaP and PC3 (as wo clea ly
dis inc models o disease p og ession) was pe o med (Table 6). The esul s
showed ha he LNCaP haplo ype can be a ilia ed in he Eu opean haplog oup
H26c, displaying he coding p i a e mu a ion in ND5 gene a posi ion 13227,
which is a synonymous polymo phism. The PC3 haplo ype belongs o ano he
Eu opean haplog oup, denomina ed U5a1c, and bea s wo non synonymous
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
126
ecen mu a ions: in gene ND4, a posi ion 11120, leading o he F121L amino
acid eplacemen , which has a Mu P ed pa hogenici y sco e o 0.423; and in
gene ND5, a posi ion 13802, conduc ing o he amino acid eplacemen T489M,
ha ing a Mu P ed pa hogenici y sco e o 0.6. We ha e in e ed, on he basis o
a la ge popula ion da ase o m DNA genomes, ha he alue o Mu P ed sco e
di iding pa hogenic mu a ions om ole a ed mu a ions is a ound 0.7. The wo
nonsynonymous mu a ions in PC3 cell line ha e sco es below his h eshold,
bu we do no know ye i he mu a ions can con ibu e addi i ely o a
pheno ype. As bo h PC3 mu a ions a e loca ed in p o eins o he Complex I, i
hey ha e some unc ional impai men in he oxida i e phospho yla ion i will be
upon his complex.
In es iga ing Complex I ac i i y in p os a e cell lines we obse ed ha in
con as wi h we we e expec ing, PC3 cells show inc eased Complex I ac i i y
(Figu e 7A). Howe e he inc eased Complex I ac i i y in PC3 cells was no
e lec ed in global cellula ATP le els (Figu e 7B). These esul s sugges ha
he p o on elec ochemical g adien ac oss he inne mi ochond ial memb ane
(IMM) is being dissipa ed and no used o ATP p oduc ion. In ac , in es iga ing
he exp ession le els o he mi ochond ial uncoupling p o ein 2 (UCP2), we
e i ied ha i is signi ican ly highe in PC3 cells, bo h using β-ac in p o ein
(p=0.02) as o al p o ein loading, and he anslocase o ou e mi ochond ial
memb ane 20 homolog (TOMM20) (p<0.01), as a mi ochond ial p o ein loading
indica ing ha PC3 cells exhibi ew mi ochond ia and hus con i ming ou
ul as uc u al da a (Figu e 8A-D).
Public genome-wide exp ession p o iling da ase s show associa ion o
me abolic- ela ed p o eins wi h disease p og ession
By making use o publicly a ailable genome-wide exp ession p o iling da ase s,
we immedia ely obse ed ha he mRNA le els o genes in ol ed in he
glycoly ic pa hway we e highe in me as a ic umou s compa ed o localized
umou s (Figu e 9A), whe eas, he di e ences in he exp ession pa e ns
obse ed o he genes in ol ed in he a y acid oxida ion pa hway we e less
s iking (Figu e 9B).
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
127
In e es ingly, looking o he genes ha codi y o lac a e anspo e p o eins,
only he mRNA le els o SLC16A3, he gene ha codi ies o MCT4, he iso o m
esponsible o lac a e ex usion we e highe in me as a ic compa ed o
localized umou s (Figu e 9E). Finally, he Glinsky da ase showed again
SLC16A3 gene being associa ed wi h he ime o biochemical ecu ence a e
su ge y (Figu e 10).
Discussion
While nume ous s udies ha e in es iga ed he in ol emen o al e ed cellula
me abolism in a ious umou s, li le is known abou he me abolic al e a ions
du ing p os a e cance p og ession.
Cos ello e al. [25,26] desc ibed he ans o ma ion o a ci a e-p oducing
epi helial cell o a malignan ci a e oxidizing, which mus be an ea ly e en o
malignancy and p og ession. Addi ionally, Shan Zha e al desc ibed he
selec i e up egula ion o pe oxisomal b anched chain a y acid β-oxida ion
pa hway in p os a e cance [17], which migh ep esen a good sou ce o ace yl-
CoA o K ebs cycle, and la e , Ranasinghe W. e al [27] linked hypoxia wi h
agg essi eness and me as asis in p os a e cance . Howe e , whe he he
exp ession o p o eins in ol ed in cellula ene ge ic me abolism is al e ed du ing
p os a e malignan ans o ma ion and p og ession, as well as, he signi icance
o hei exp ession is la gely unknown.
In his s udy, we ound a consis en o e exp ession o p o eins in ol ed in
pe oxisomal b anched chain a y acid oxida ion in p os a e cance as well as in
PIN lesions in con as o benign glands, sugges ing a possible e iological ole
o his pa hway in malignan ans o ma ion. In he o he hand, he exp ession o
p o eins in ol ed in he glycoly ic pa hway showed associa ion wi h eliable
p edic o s o poo p ognosis such as umou s age (pT), Gleason sco e and
biochemical ecu ence, sugges ing a ole in disease p og ession.
Acco dingly, ou in i o s udies showed ha di e en models o disease
p og ession exhibi ed di e en me abolic p o iles. The cell lines de i ed om
dis an me as asis a e mo e glycoly ic and s ongly exp ess MCT4 and GLUT-1
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
128
a he plasma memb ane, wo majo playe s in he glucose up ake and lac a e
ex usion essen ial o he p ope unc ion o he glycoly ic pa hway. Impo an ly,
a change in he subcellula localiza ion o hese p o eins om localized umou
o me as a ic umou was e i ied, wi h MCT4, GLUT1 and CAIX being p esen
a he plasma memb ane only in me as a ic samples, sugges ing an ob ious link
be ween he plasma memb ane unc ion o hese p o eins and he agg essi e
s age o he umou .
Using inhibi o s o he di e en pa hways we we e able o suppo he idea ha
di e en me abolic pa hways a e ac i e acco ding o he disease s age o he
umou . Thus, a ge ing a y acid oxida ion seems o be mo e ele an in an
ea ly s age in con as o he glycoly ic pa hway, which will p oduce mo e e ec s
in an ad anced s age o he disease.
Addi ionally, di e ences we e also e iden a he o ganelle con en le el,
be ween low and high umo igenic models, which led us o in es iga e he idea
o a less ene ge ically e icien espi a ion o he highly umo igenic models. In
ac , we ound an alse inc ease in Complex I ac i i y in PC3 cells masked by
he o e exp ession o UCP2 p o ein, jus i ying a coupling de ec in oxida i e
phospho yla ion in hese cells. In e es ingly, a coupling de ec in oxida i e
phospho yla ion was also desc ibed in mi ochond ion- ich (Hü hle o oncocy ic)
umou s o he hy oid [28-31].
Finally, publici y da ase suppo ed ou main indings showing ha he
exp ession o genes in ol ed in a y acid oxida ion mos ly changed om benign
samples o localized umou specimens, sugges ing a clea ole mainly in
p os a e malignan ans o ma ion a he han p og ession, whe eas, genes
in ol ed in he glycoly ic me abolism a e abe an ly exp essed mainly in he
me as a ic samples, being mo e compa ible wi h a ole in p os a e cance
p og ession and agg essi eness, and d awing a en ion in his case o
SLC16A3 gene ha codi ies MCT4 as a p edic i e ma ke o disease
p og ession and agg essi eness. This da a also indica es ha p os a e cance
does no i in he adi ional model o a me abolic swi ch o glycolysis om non
malignan o malignan cells bu ins ead his me abolic swi ch is mo e likely o
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
129
be in ol ed in he ad anced s age o he disease and impo an ly p io o
pa hologic ans o ma ion, exhibi ing a p edic i e alue.
To he bes o ou knowledge, his is he la ges s udy in es iga ing he ole o
key me abolic- ela ed p o eins in ela ion o ou come o adical ea men o
localized p os a e cance , pu ing oge he a la ge a ie y o clinical samples
and in i o models, demons a ing he me abolic he e ogenei y o p os a e
cance and i s signi icance as diagnos ic, p ognos ic and he apeu ic ool in
p os a e cance disease.
Acknowledgemen s
NPG and SS ecei ed ellowships om he Po uguese Founda ion o Science
and Technology (FCT), e s. SFRH/BD/61027/2009 and PTDC/SAU-
MET/113415/2009 espec i ely. This wo k was suppo ed by he FCT g an e .
PTDC/SAU-MET/113415/2009, unde he scope o “P og ama Ope acional
Tema ico Fac o es de Compe i i idade” (COMPETE) o “Quad o Comuni a io
de Apoio III” and co- inanced by Fundo Comuni a io Eu opeu FEDER. This
wo k was pa ially suppo ed by he p ojec (PIC/IC/83037/2007). Fu he
unding was ob ained om he p ojec ‘Mic oen i onmen , me abolism and
cance ’ based a IPATIMUP and pa ially suppo ed by P og ama Ope acional
Regional do No e (ON.2—O No o No e), unde he Quad o de Re e ência
Es a égico Nacional (QREN), and h ough he Fundo Eu opeu de
Desen ol imen o Regional (FEDER). IPATIMUP and ICVS/3Bs a e associa e
labo a o ies o he Po uguese Minis y o Science, Technology and Highe
Educa ion and is pa ially suppo ed by he FCT.

Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
130
S a emen o au ho con ibu ions
All au ho s mee he c i e ia o au ho ship in ha hey ha e pa icipa ed in he
concep ion, execu ion o in e p e a ion o a leas pa o he publica ion in hei
ield o expe ise.
All au ho s ead and app o ed he inal manusc ip .
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
131
Re e ences
1. Wa bu g, O., F. Wind, and E. Negelein, The Me abolism o Tumo s in he Body. J Gen
Physiol, 1927. 8(6): p. 519-30.
2. Mi anda-Goncal es, V., e al., Monoca boxyla e anspo e s (MCTs) in gliomas:
exp ession and exploi a ion as he apeu ic a ge s. Neu o Oncol, 2013. 15(2): p. 172-88.
3. Pinhei o, C., e al., Role o monoca boxyla e anspo e s in human cance s: s a e o he
a . J Bioene g Biomemb , 2012. 44(1): p. 127-39.
4. Pinhei o, C., e al., Exp ession o monoca boxyla e anspo e s 1, 2, and 4 in human
umou s and hei associa ion wi h CD147 and CD44. J Biomed Bio echnol, 2010. 2010:
p. 427694.
5. Pinhei o, C., e al., Monoca boxyla e anspo e s 1 and 4 a e associa ed wi h CD147 in
ce ical ca cinoma. Dis Ma ke s, 2009. 26(3): p. 97-103.
6. Pinhei o, C., e al., Inc easing exp ession o monoca boxyla e anspo e s 1 and 4
along p og ession o in asi e ce ical ca cinoma. In J Gynecol Pa hol, 2008. 27(4): p.
568-74.
7. Pinhei o, C., e al., Inc eased exp ession o monoca boxyla e anspo e s 1, 2, and 4 in
colo ec al ca cinomas. Vi chows A ch, 2008. 452(2): p. 139-46.
8. Pe ega-Gomes, N., e al., Monoca boxyla e anspo e 2 (MCT2) as pu a i e
bioma ke in p os a e cance . P os a e, 2012.
9. Pe ega-Gomes, N., e al., Monoca boxyla e anspo e 4 (MCT4) and CD147
o e exp ession is associa ed wi h poo p ognosis in p os a e cance . BMC Cance ,
2011. 11: p. 312.
10. Higgins, L.H., e al., Hypoxia and he me abolic pheno ype o p os a e cance cells.
Biochim Biophys Ac a, 2009. 1787(12): p. 1433-43.
11. E e , P., e al., Exp ession o glucose anspo e 1 (Glu -1) in cell lines and clinical
specimens om human p os a e adenoca cinoma. An icance Res, 2004. 24(5A): p.
3057-63.
12. S ewa , G.D., e al., Analysis o hypoxia-associa ed gene exp ession in p os a e
cance : lysyl oxidase and glucose anspo e -1 exp ession co ela e wi h Gleason
sco e. Oncol Rep, 2008. 20(6): p. 1561-7.
13. Vaz, C.V., e al., And ogen- esponsi e and non esponsi e p os a e cance cells p esen
a dis inc glycoly ic me abolism p o ile. In J Biochem Cell Biol, 2012. 44(11): p. 2077-
84.
14. Gio acchini, G., e al., [11C]choline posi on emission omog aphy/compu e ized
omog aphy o es age p os a e cance cases wi h biochemical ailu e a e adical
p os a ec omy and no disease e idence on con en ional imaging. J U ol, 2010. 184(3):
p. 938-43.
15. Hong, H., e al., Posi on emission omog aphy imaging o p os a e cance . Amino
Acids, 2010. 39(1): p. 11-27.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
132
16. Fa sad, M., e al., Posi on-emission omog aphy in imaging and s aging p os a e
cance . Cance Bioma k, 2008. 4(4-5): p. 277-84.
17. Zha, S., e al., Pe oxisomal b anched chain a y acid be a-oxida ion pa hway is
up egula ed in p os a e cance . P os a e, 2005. 63(4): p. 316-23.
18. Liu, Y., L.S. Zuckie , and N.V. Ghesani, Dominan up ake o a y acid o e glucose by
p os a e cells: a po en ial new diagnos ic and he apeu ic app oach. An icance Res,
2010. 30(2): p. 369-74.
19. Lobo-da-Cunha, A., e al., His ochemical and ul as uc u al cha ac e iza ion o he
pos e io esophagus o Bulla s ia a (Mollusca, Opis hob anchia). Mic osc Mic oanal,
2010. 16(6): p. 688-98.
20. And ews, R.M., e al., Reanalysis and e ision o he Camb idge e e ence sequence o
human mi ochond ial DNA. Na Gene , 1999. 23(2): p. 147.
21. Pe ei a, L., e al., The di e si y p esen in 5140 human mi ochond ial genomes. Am J
Hum Gene , 2009. 84(5): p. 628-40.
22. Li, B., e al., Au oma ed in e ence o molecula mechanisms o disease om amino acid
subs i u ions. Bioin o ma ics, 2009. 25(21): p. 2744-50.
23. Pe ei a, L., e al., Compa ing phylogeny and he p edic ed pa hogenici y o p o ein
a ia ions e eals equal pu i ying selec ion ac oss he global human m DNA di e si y.
Am J Hum Gene , 2011. 88(4): p. 433-9.
24. Kloss-B ands a e , A., e al., HaploG ep: a as and eliable algo i hm o au oma ic
classi ica ion o mi ochond ial DNA haplog oups. Hum Mu a , 2011. 32(1): p. 25-32.
25. Cos ello, L.C. and R.B. F anklin, The clinical ele ance o he me abolism o p os a e
cance ; zinc and umo supp ession: connec ing he do s. Mol Cance , 2006. 5: p. 17.
26. Cos ello, L.C., e al., Zinc and p os a e cance : a c i ical scien i ic, medical, and public
in e es issue (Uni ed S a es). Cance Causes Con ol, 2005. 16(8): p. 901-15.
27. Ranasinghe, W.K., e al., The ole o hypoxia-inducible ac o 1alpha in de e mining he
p ope ies o cas a e- esis an p os a e cance s. PLoS One, 2013. 8(1): p. e54251.
28. Maximo, V., e al., The biology and he gene ics o Hu hle cell umo s o he hy oid.
Endoc Rela Cance , 2012. 19(4): p. R131-47.
29. Maximo, V., e al., Mi ochond ial DNA soma ic mu a ions (poin mu a ions and la ge
dele ions) and mi ochond ial DNA a ian s in human hy oid pa hology: a s udy wi h
emphasis on Hu hle cell umo s. Am J Pa hol, 2002. 160(5): p. 1857-65.
30. Sa agne , F., e al., De ec i e mi ochond ial ATP syn hesis in oxyphilic hy oid umo s. J
Clin Endoc inol Me ab, 2001. 86(10): p. 4920-5.
31. Gaspa e, G., e al., Dis up i e mi ochond ial DNA mu a ions in complex I subuni s a e
ma ke s o oncocy ic pheno ype in hy oid umo s. P oc Na l Acad Sci U S A, 2007.
104(21): p. 9001-6.
Role o MCTs in P os a e Ca cinoma Pé ega-Gomes N.
133
Tables
Table 1. De ails o he immunohis ochemical p ocedu e used o analyze he exp ession o he
di e en p o eins.
P o ein
An ibody
Company
An ibody
Dilu ion
Posi i e
Con ol
Incuba ion
Pe iod
De ec ion
Sys em
MCT4
sc-50329
San a C uz
Bio echnology
1:500
Colon umo
O e nigh
R.T.U. Vec as ain
Uni e sal Eli e ABC
Ki , Vec o , EUA
MCT2
sc-50322
San a C uz
Bio echnology
1:200
Muscle
2 hou s
Ul a ision
De ec ion Sys em
An i-poly alen ,
HRP, Lab ision
Co po a ion,
F eemon , CA
CD44
156-3C11
Se o ec
1:1000
Colon umo
GLUT1
ab 15309
Abcam
1:2000
Head and neck
umo
CAIX
ab 15086
Abcam
1:2000
S omach
MCT1
sc-365501
San a C uz
Bio echnology
1:500
Colon umo
O e nigh
R.T.U. Vec as ain
Uni e sal Eli e ABC
Ki , Vec o , EUA
HIF-1α
610958
BD
Biosciences
1:100
Glioblas oma
GLUT12
ab 75441
Abcam
1:500
Rim
O e nigh
Ul a ision
De ec ion Sys em
An i-poly alen ,
HRP, Lab ision
Co po a ion,
F eemon , CA
LDHV
ab 53010
Abcam
1:1000
Colon umo
2 hou s
HKII
ab104836
Abcam
1:750
Colon umo
PDK1
ab110025
Abcam
1:500
S omach
CD147
sc-71038
San a C uz
Bio echnology
1:400
Colon umo
AMACR
504R-16
Cell Ma que
1:50
Kidney
ACOX3
sc-135435
San a C uz
Bio echnology
1:250
Li e
DBP
DBP an ibody was a gi
om D . Gab iele Molle
om Helmhol zZen um
mÜnchen.
Ready o
use
Kidney